SERUM CARTILAGE OLIGOMERIC MATRIX PROTEIN: A BIOMARKER FOR ACUTE ARTICULAR CARTILAGE DAMAGE by Hoch, Johanna M.
University of Kentucky 
UKnowledge 
Theses and Dissertations--Rehabilitation 
Sciences Rehabilitation Sciences 
2012 
SERUM CARTILAGE OLIGOMERIC MATRIX PROTEIN: A 
BIOMARKER FOR ACUTE ARTICULAR CARTILAGE DAMAGE 
Johanna M. Hoch 
University of Kentucky, johannaclark722@gmail.com 
Right click to open a feedback form in a new tab to let us know how this document benefits you. 
Recommended Citation 
Hoch, Johanna M., "SERUM CARTILAGE OLIGOMERIC MATRIX PROTEIN: A BIOMARKER FOR ACUTE 
ARTICULAR CARTILAGE DAMAGE" (2012). Theses and Dissertations--Rehabilitation Sciences. 3. 
https://uknowledge.uky.edu/rehabsci_etds/3 
This Doctoral Dissertation is brought to you for free and open access by the Rehabilitation Sciences at UKnowledge. 
It has been accepted for inclusion in Theses and Dissertations--Rehabilitation Sciences by an authorized 
administrator of UKnowledge. For more information, please contact UKnowledge@lsv.uky.edu. 
STUDENT AGREEMENT: 
I represent that my thesis or dissertation and abstract are my original work. Proper attribution 
has been given to all outside sources. I understand that I am solely responsible for obtaining 
any needed copyright permissions. I have obtained and attached hereto needed written 
permission statements(s) from the owner(s) of each third-party copyrighted matter to be 
included in my work, allowing electronic distribution (if such use is not permitted by the fair use 
doctrine). 
I hereby grant to The University of Kentucky and its agents the non-exclusive license to archive 
and make accessible my work in whole or in part in all forms of media, now or hereafter known. 
I agree that the document mentioned above may be made available immediately for worldwide 
access unless a preapproved embargo applies. 
I retain all other ownership rights to the copyright of my work. I also retain the right to use in 
future works (such as articles or books) all or part of my work. I understand that I am free to 
register the copyright to my work. 
REVIEW, APPROVAL AND ACCEPTANCE 
The document mentioned above has been reviewed and accepted by the student’s advisor, on 
behalf of the advisory committee, and by the Director of Graduate Studies (DGS), on behalf of 
the program; we verify that this is the final, approved version of the student’s dissertation 
including all changes required by the advisory committee. The undersigned agree to abide by 
the statements above. 
Johanna M. Hoch, Student 
Dr. Carl G. Mattacola, Major Professor 
Dr. Anne D. Olson, Director of Graduate Studies 
SERUM CARTILAGE OLIGOMERIC MATRIX PROTEIN: A BIOMARKER FOR 
ACUTE ARTICULAR CARTILAGE DAMAGE 
 
 
 
_________________________________ 
DISSERTATION 
_________________________________ 
A dissertation submitted in partial fulfillment of the requirements  
for the degree of Doctor of Philosophy in the College of Health Sciences 
at the University of Kentucky 
 
By 
Johanna M. Hoch 
 
Lexington, Kentucky 
Co-Directors:  Dr. Carl G. Mattacola, Full Professor of Athletic Training  
  and Dr. Lori S. Gonzalez, Full Professor of Communication Sciences & Disorders 
 
Lexington, Kentucky 
 
2012 
 
 
 
 
Copyright © Johanna Marie Hoch 2012
ABSTRACT OF DISSERTATION 
 
 
SERUM CARTILAGE OLIGOMERIC MATRIX PROTEIN: A BIOMARKER FOR 
ACUTE ARTICULAR CARTILGE DAMAGE 
  
 Bone bruise lesions (BBL) are documented on MRIs diagnosing acute knee 
ligament injury (AKLI). Recent evidence has indicated that a majority of patients that 
sustain an AKLI, especially anterior cruciate ligament (ACL) knee injury, will develop 
post-traumatic osteoarthritis (PTOA) 10-20 years following injury. It has been proposed 
that the initial damage sustained to the articular cartilage overlying BBL causes a cascade 
of events that may result in PTOA.  
 Researchers have proposed a modification to treatment protocols for more severe 
BBL, or have stressed the need for the development of protective therapies to protect the 
articular cartilage. However, there are limited tools available to evaluate the clinical 
outcome of articular cartilage overlying BBL. Furthermore, damage to the cartilage 
overlying BBL may be different according to differing BBL severities. Therefore, the use 
of a cartilage degradation biomarker, serum cartilage oligomeric matrix protein (sCOMP) 
and the use of a BBL severity classification system may be useful to determine if 
differences exist between patients with and without BBL, and with differing BBL 
severities.  
The purpose of this dissertation was to investigate the utility of sCOMP as a 
biomarker for acute articular cartilage damage. The purposes of these studies were to 
determine the inter and intraday reliability of this marker, to document sCOMP 
longitudinally in collegiate athletes and following AKLI, and to determine if differences 
in sCOMP and self-reported pain and function exist for patients with and without BBL, 
and differing BBL following AKLI. 
 The results of these studies indicated sCOMP measures had strong inter and 
intraday reliability. Additionally, exercise does seem to influence sCOMP levels; 
however, these elevations may not be clinically meaningful. Furthermore, sCOMP levels 
were not different between patients with BBL and without, and between differing  
BBL severities. The results of these studies support the use of a BBL severity classification for 
future research studies in order to further elucidate the outcomes of these lesions. 
 
Keywords: Articular cartilage, Biomarkers, Bone Bruise Lesions, Acute Knee Ligament Injury, 
Patient Reported Outcome 
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Chapter One: Introduction 
Background 
 It is estimated that approximately 80,000 to 250,000 anterior cruciate ligament 
(ACL) injuries occur each year.29 Regardless of whether the ligament is reconstructed; 
these patients have a 50% likelihood of developing posttraumatic osteoarthritis (PTOA) 
10-20 years after joint injury.54, 57, 91, 99 Numerous investigations have been conducted 
with the primary aim of identifying contributing risk factors for PTOA development 
following ACL injury.52, 64, 74, 77, 87, 88 However, the underlying mechanism associated 
with the development of PTOA following ACL injury is not clear. Numerous 
investigators have turned their attention to the damage sustained by the articular cartilage 
that overlies concomitant bone bruise lesions (BBL) associated with ACL injury, and the 
role the damage to the articular cartilage and underlying subchondral bone may play in 
the development of PTOA.13, 24, 71, 79  The purpose of this review is to provide an 
overview of the severity classification systems, and volumetric measuring techniques for 
acute BBL associated with acute knee ligament injury (AKLI). The second purpose of 
this review is to provide evidence from patients studied at the time of ACL reconstruction 
(ACLR), documenting damage to articular cartilage overlying BBL, and to review 
articular cartilage scoring systems that have been used to evaluate the damage sustained 
to the articular cartilage overlying BBL arthroscopically. In addition, this review will 
summarize the current evidence provided by studies investigating cartilage oligomeric 
matrix protein (COMP) associated with AKLI and the role this biomarker may play in 
elucidating the development of PTOA following ACL injury and acute articular cartilage 
damage. Finally, this review will summarize the current evidence regarding differences in 
2 
 
self-reported pain and function for patients with AKLI, with and without concomitant 
BBL. 
Bone bruise lesions 
 Bone bruise lesions (BBL) are defined as traumatically involved, geographic, and 
non-linear areas of signal loss involving the subcortical bone on T-1 weighted magnetic 
resonance images (MRI) and areas of increased signal intensity on T-2 weighted images, 
and are not evident on plain radiographs.66, 94 Following ACL injury, these lesions are 
most often located in the lateral compartment of the tibiofemoral joint,7, 18, 59, 76, 84, 98 and 
are present on an estimated 80% of MRIs diagnosing ACL injury.59, 84, 90, 94 These lesions 
have also been documented on MRIs used to diagnose injuries to the posterior cruciate 
ligament (PCL),61 medial collateral ligament (MCL)65 and posterolateral corner (PLC) 
complex.28, 94 In addition to documenting the commonality and location of these injuries 
in association with ligament injuries, studies have also classified these lesions into 
differing categories,94 severity classifications18, 59 and have developed methods to 
measure the volume of the lesions.20, 78, 81  
 Bone bruise classification systems 
  Bone bruise lesions have been classified into five categories: reticular, 
geographic, linear, impaction and osteochondral fractures.94 Reticular lesions were 
defined as “regions of reticular, serpiginous stranding of diminished signal intensity on 
T1-weighted images within the epiphyseal and metaphyseal marrow” (page 272).94 These 
lesions were distant from the cortical bone of the subjacent articular surface and were 
often the result of focal cortical impaction (page 272).94  
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 The term geographic was characterized by the “contiguity to the subjacent cortical 
bone, which may demonstrate focal cortical impaction” (page 273).94 Geographic occult 
lesions were further classified into Type I and Type II geographic lesions. Type I 
geographic lesions were defined as “coalescent with the exception of their periphery, 
which may demonstrate evidence of reticulation of the adjacent, contrasting, high-signal-
intensity epiphyseal fat” (page 273).94 Type II geographic lesions were defined as 
“coalescent, crescent like lesions demarcating a circumscribed central zone of marrow fat 
abutting the subjacent cortical bone” (page 273).94   
 Linear occult subcortical fractures were defined as “discrete linear regions of 
diminished signal intensity on T1-weighted images” (page 273).94 Impaction fractures 
were fractures that “occurred in conjunction with the geographic or reticular fractures and 
showed variable degrees of depression of the osteochondral surface” (age 273).94 
Osteochondral fractures were described as “either occult or overt lesions identified as 
discrete adherent or distracted cortical fractures that contain an intact cartilage surface” 
(page 273).
94
  
 Following a prospective investigation of  the prevalence of occult subcortical 
fractures for patients with acute knee joint effusions, findings yielded a total of 70% of 
the occult lesions documented on MRI were reticular, and 22% of the lesions were 
geographic Type I and Type II lesions, 5% were impaction fractures, 0.6% were linear 
fractures and 0.6% were osteochondral fractures.
94
 In addition, 81% of the lesions were 
documented on the lateral compartment of the tibiofemoral joint.
94
 Finally, this study 
confirmed occult fractures are present for patients with injury to the ACL, PCL, MCL 
and the lateral collateral ligament (LCL).
94
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 Bone bruise severity classification systems 
 There are few published classification systems used to classify BBL severity 
(Table 1.1).
18, 59
 Lynch et al. classified BBL into three distinct categories: Type I, Type II 
and Type III lesions (Table 1.1).
59
 Following a retrospective review of 434 MRIs, 87 
patients had BBL visible on MRI for a total of 142 lesions.
59
 Of the 142 lesions, 99 were 
Type I, 19 were Type II and 24 were Type III lesions.
59
 In addition, arthroscopic 
documentation of the overlying articular cartilage was available for a portion of the 
patients, indicating 28% of the Type I and Type II lesions and 75% of the Type III lesions 
had associated changes to the overlying articular cartilage.
59
    
 In addition to the Lynch et al.
59
 classification system, Costa-Paz  (Figure 1.1)  
classified BBL into three distinct categories: Type I, Type II and Type III lesions (Table 
1.1).
18
 The results of the pre-operative MRI review revealed a total of 29 BBL with 13 
Type I, 11 Type II and 5 Type III lesions.
18
  
 It is of interest to note that Type I lesions for each of the severity classifications 
were identified the most frequently in each of their studies. Also, Lynch and associates
59
 
reported more Type III lesions than Type II lesions while Costa-Paz
18
 reported very few 
Type III lesions. One of the major differences in these classification systems is the 
definition of the Type III lesion. Lynch et al.
59
 describes the Type III lesion as having no 
cortical disruption as Costa-Paz
18
 describes the Type III lesion as having disruption or 
depression of the cortical surface.  
 Volumetric measurements of bone bruise lesions 
 Volumetric measuring techniques have also been developed to measure the 
volume of BBL utilizing images on MRI viewing software.  Roemer and Bohndorf 
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developed a method to quantify the volume of BBL using a three dimensional method 
(Figure 1.2).
81
 The volume of each of the BBL was determined by following three steps 
while using the largest amount of signal change in the coronal images.
81
 First, a straight 
line was drawn from the most peripheral margins of the BBL (line a),  second, a bisecting 
line was drawn (line b), and in the sagital plane a straight line was drawn to connect the 
peripheral margins of the BBL (line c).
81
 Volume was then calculated using the formula 
volume= a x b x c.
81
 The results of their study indicated that the average size of the BBL 
was 14.75cm
3
.
81
 
 A different volumetric technique was described by Paakkala et al. to measure the 
volume of BBL associated with acute, traumatic patellar dislocations.
78
 To measure bone 
bruise volume, the BBL area (mm
2
) was traces for each image slice (slice thickness was 
3mm gap between slices was 0.3mm).
78
 The bone bruise volume was then calculated 
using the following formula: volume= mm
2
 x 3.3mm.
78
 The results of their study 
indicated the median volume for BBL on the femur were 25,831mm
3 
and the lesions on 
the patella had a median volume of 2,832mm
3
.
78
 
 Davies and associates also measured BBL volume for patients who suffered acute 
knee injury.
20
 For the purposes of their investigation, BBL volume was calculated by 
measuring the background noise for each of the patients and drawing a region of interest 
around the tibial plateau and femoral condyles.
20
 The total cross-sectional area of the 
BBL was calculated and multiplied by the slice thickness (4mm in the case of this study) 
and summed for a total volume of each bone bruise.
20
 The results of their study indicated 
that patients who suffered ACL injury had a median BBL volume of 40.5cm
3
 and patients 
who suffered a collateral ligament injury had a median BBL volume of 38.4cm
3
.
20
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 While these methods of measuring volume are slightly different, is appears the 
final outcomes are similar. When converting the mm
3
 to cm
3
, it appears the average BBL 
volume ranges from 14.75cm
3
 
81
 to 40.5cm
3
.
 20
 While the data for specific compartments 
were not available (lateral femoral condyle (LFC), medial femoral condyle (MFC), lateral 
tibial plateau (LTP) and medial tibial plateau (MTP)), it would be of interest to determine 
if differences in volume exist between each of the compartments. 
Acute articular cartilage injury following ACL injury 
 Damage to the articular cartilage overlying BBL is not frequently visible on 
MRI;
49, 66
 however, there have been reports of visible damage ranging from chondral 
softening to chondral defect during arthroscopy.
41, 59, 76, 91
 Arthroscopic inspection of the 
articular cartilage overlying BBL in 10 patients undergoing ACLR revealed chondral 
softening when probed (n=4), visible fissuring or fibrillation (n=5) and 1 patient with a 
chondral defect (Table 1.2).
41
 Additionally, another report noted that 94% of ACLR 
patients had visible articular cartilage damage in the LFC and 80% had visible articular 
cartilage damage overlying the BBL in the LTP.
76
 Of the 34 patients with articular 
cartilage injuries (included patients with BBL and without BBL) to the LTP, 18 were 
classified as ICRS Grade I and 11 cases were classified as ICRS Grade 2 (Table 1.2).
76
 In 
a third report, 46% of the patients undergoing ACLR had visible fractures and cracks in 
the articular cartilage overlying BBL.
91
 The results of these studies indicate that damage 
occurs to the articular cartilage overlying BBL following ACL injury. Understanding the 
extent of damage to the articular cartilage matrix and chondrocytes is the next step in 
further understanding the clinical outcome of the damage to the articular cartilage that 
overlies BBL. 
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 Recent basic science evidence has indicated that the articular cartilage overlying 
BBL suffers substantial damage that may not be repairable and this may serve as the first 
stage in the PTOA process.
24, 41
 Following biopsies of the articular cartilage overlying 
BBL, Johnson et al.
41
 reported 4 of 10 patients had evidence of chondrocyte death and 
matrix degeneration and 2 of the patients had chondrocyte death and severe matrix 
degeneration throughout the depth of the articular cartilage. Furthermore, loss of the 
proteoglycan component in the extracellular matrix was also identified in patients with 
BBL.
24
 This evidence confirms that the impact associated with BBL during acute ACL 
injury also causes damage to the overlying articular cartilage and that this damage can be 
severe. Damage to the articular cartilage may start the clinical cascade of degenerative 
changes, as the integrity of the matrix may be unable to overcome such severe damage.
24, 
71
  However, at this time there are no cost-effective minimally invasive objective tools 
with which to prospectively measure the extent of articular cartilage damage and the 
clinical course associated with this injury.  
Serum cartilage oligomeric matrix protein 
 The relationship between ACL injury and PTOA development could be better 
elucidated with an improved ability to identify the extent of the articular cartilage 
damage, to monitor it longitudinally and to understand its long term ramifications.
24, 47, 58
 
Serum or synovial fluid biomarkers, specifically cartilage degradation markers, may be 
useful objective tools with which to prospectively measure the extent and course of 
increased turnover, or chondrocyte death and loss of extracellular matrix following ACL 
rupture
5, 24, 47
  and provide the means for prospective monitoring. 
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 Data on biomarkers that were studied specifically in patients with ACL injury and 
articular cartilage injury is sparse. However, one biomarker that has been studied in 
patients with AKLI is cartilage oligomeric matrix protein (COMP). COMP is a cartilage 
degradation biomarker that is primarily identified in articular cartilage and plays an 
important role in the maintenance of the extracellular matrix.
22, 47, 93
 Increases in synovial 
fluid and serum COMP levels have been reported for patients following acute knee 
injury.
19, 47, 58
 In a cross-sectional study, patients with an ACL injury had significant 
increases in synovial fluid COMP levels compared to healthy controls.
58
 However, there 
were no differences in serum COMP levels between the healthy and injured groups.
58
 
Furthermore, the authors reported that the largest differences in synovial fluid COMP 
levels for the ACL or meniscus group were measured when the samples were taken as 
close to the time of injury as possible.
58
 In addition, increases in synovial fluid COMP 
levels were still present 6-12 months after ACL or meniscus injury, compared to a 
healthy reference group.
58
 In summary, the results of Lohmander et al.
58
 indicate that 
synovial fluid COMP levels are increased following ACL injury compared to healthy 
controls and these levels are highest when the sample is collected as close to the time of 
injury as possible. In addition, their results indicate there are no differences in serum 
COMP levels between patients with ACL injury compared to controls.
58
 
 Synovial fluid COMP differences for patients with acute knee injury were also 
reported in a cross-sectional study investigating increases in synovial fluid COMP levels 
following acute knee injury.
19
 Patients with acute knee injury (type of injuries ranged 
from collateral and cruciate ligament injury, meniscus or isolated cartilage injury) were 
divided into three groups; acute (samples collected less than 4 weeks from time of 
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injury), sub acute (samples collected 4-52 weeks from injury) and chronic (samples 
collected more than one year after injury).
19
 Patients in the acute and chronic group had 
increased synovial fluid COMP levels compared to healthy controls.
19
 In addition, it was 
reported that synovial fluid COMP levels in the uninjured knee for the acute and chronic 
group were increased when compared to the healthy control synovial fluid COMP 
levels.
19
 Interestingly there were no differences in synovial fluid COMP levels in this 
study between the injured and uninjured knees for patients with acute knee injury.
19
 
However, it must be noted that while the authors report only patients without 
radiographic osteoarthritis (OA) were included, only the injured knee was viewed 
arthroscopically and radiographically. Synovial fluid COMP levels may have been 
similar between the injured and uninjured knees because the uninjured knee had 
radiographic signs of OA that were not discovered. The results of this study further 
corroborate the evidence that there are increases in COMP levels following acute knee 
injury.
19
  
 Serum COMP levels have also been studied longitudinally following AKLI and 
subsequent arthroscopy in a group of athletes.
47
 For patients with cruciate ligament and or 
meniscus injury, serum COMP at the time of surgery was significantly increased 
compared to the healthy controls.
47
 It was also noted that there was a trend for serum 
COMP levels to increase the first year following surgery and there was a decrease in 
serum COMP at the two years following surgery for most subjects.
47
 However, a 
subgroup of patients had an increase in serum COMP two years post surgery and it was 
concluded that these patients may be at a higher risk of developing PTOA.
47
 
Interestingly,  these and the previous results indicate a significant difference in serum 
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COMP levels, while Lohmander et al.
58
 reported no differences in serum COMP levels 
between injured patients and healthy controls. While the time from injury to serum 
collection was similar for both studies, it could be hypothesized that the patients in the 
Kuhne et al.
47
 study had more severe articular cartilage damage compared to the patients 
in the Lohmander et al. study.
58
 Therefore, it appears that it is important to present data 
regarding concomitant injuries, such as articular cartilage damage or BBL identified 
either by MRI or arthroscopy, as these data may elucidate why differences in serum or 
synovial fluid exist for patients with AKLI when compared to healthy controls.  
 A recent investigation documented COMP levels following acute ACL injury and 
described changes from time of injury to ACLR.
13
 A total of 11 patients with acute ACL 
injury and concomitant injuries such as BBL, meniscus tears and chondral defects had 
serum and synovial fluid COMP levels measured acutely after injury (15±12 days) and at 
the time of ACLR (48±12 days after injury).
13
 Interestingly, the authors reported a trend 
of decreasing synovial fluid COMP levels from time of injury to time of surgery.
13
 These 
results indicate that this marker is elicited immediately following acute articular cartilage 
injury and supports the previous recommendations that serum or synovial fluid samples 
should be collected as close to the time of injury as possible
58
 as it may provide a means 
to quantifying the extent of damage.  
 Histology and immunostaining for COMP has also been performed on articular 
cartilage biopsies for patients who suffered an ACL injury and had concomitant BBL.
24
 A 
total of 13 patients with ACL injury and concomitant BBL had synovial fluid samples 
and biopsies of the articular cartilage collected at the time of arthroscopy.
24
 The 
immunohistochemical staining revealed a distribution of COMP in the articular cartilage 
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that is similar to the COMP distribution that would be found for patients with OA.
24
 In 
addition, Western blot analysis indicated there was a large amount of COMP fragments in 
the synovial fluid from the injured knee.
24
 This report indicated synovial fluid COMP 
levels were higher in the injured knee compared to the uninjured knee.
24
 Based on these 
results it appears that COMP is a promising marker for future research studies that 
investigate the damage to articular cartilage following acute knee injury and the PTOA 
development process.  
 Biomarkers can be used to diagnose disease, monitor disease progression, or 
determine the efficacy of therapeutic interventions.
55
 As summarized here, there are 
differences in cartilage degradation biomarkers detected between patients with AKLI 
when compared to healthy controls.
19, 47, 58
 It  has been suggested that the damage 
sustained by the articular cartilage during acute ACL injury is irreversible and immediate 
treatment to slow the degradative process might be warranted.
13
 Given that BBL are 
present on an estimated 80% or higher of MRIs diagnosing ACL injury
59, 84, 90, 94
 and that 
damage to the articular cartilage overlying these lesions has been well documented,
24, 41, 
76, 91
  it is rational to presume that biomarkers of cartilage metabolism are tools that might 
provide insights into the degree of articular cartilage damage and its deleterious effect on 
overall joint health.  
 In order for a biomarker to be effective for diagnosing disease or monitoring 
disease progression, it must be sensitive to differences between healthy individuals and 
those with cartilage damage and among varying degrees of severity.
3, 14, 15
 One limitation 
to many of the studies investigating changes in serum or synovial fluid COMP for 
patients following ALKI
13, 19, 47, 58
 is the lack of reporting of concomitant injuries to the 
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articular cartilage. It is reasonable to hypothesize that a majority of these patients had a 
concomitant BBL and damage to the articular cartilage overlying this area. Therefore, 
data documenting the extent of concomitant BBL and articular cartilage injuries are 
needed to further investigate if differences in serum or synovial fluid cartilage 
degradation biomarker levels exist for patients following AKLI when compared to 
healthy controls.  
 Cartilage degradation biomarkers must also be sensitive to varying degrees of 
severity of acute articular cartilage damage in order to be used for future research 
studies.
3, 14, 15
 A recent systematic review and meta-analysis revealed larger effect sizes 
for more patients with more severe OA when compared to healthy controls, indicating 
that sCOMP is sensitive to OA severity.
35
 While sCOMP is sensitive to OA severity, a 
chronic articular cartilage disease;
15, 35
 there is no evidence to suggest COMP is sensitive 
to differing severities of acute articular cartilage damage. Therefore, incorporating a 
method of measuring the severity of articular cartilage damage at time of arthroscopy for 
patients following acute knee injury in order to assess the sensitivity of these biomarkers 
to the severity of articular cartilage damage is warranted.  
Effects of bone bruise lesions on pain and function pre-operatively 
 There is inconsistent evidence investigating the short term effects of BBL on pain 
and function in patients with AKLI with concomitant BBL. It has been reported that 
patients with acute ACL injury and concomitant BBL had greater levels of self-reported 
pain and loss of function compared to patients without BBL.
42
 Furthermore, it was 
reported patients with BBL had longer lasting effusions and needed a longer period of 
time to achieve normal gait compared to patients without BBL.
42
 In addition, patients 
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with intra-articular knee pathology who also had BBL  had poorer function measured by 
the Noyes scale.
97
 However there was no difference in function, as measured by the 
Noyes scale, six months post injury when compared to patients without BBL.
97
  
 In contrast, no significant differences in self-reported pain scores between acute 
knee injured patients with and without BBL documented on MRI has been reported.
6
 
Patients who had an acute knee injury completed a numeric pain scale at the time of their 
MRI and patients who had a documented BBL on MRI reported a baseline pain score of 
4.15 compared to the no BBL group that reported an average pain score of 3.88 
(p=0.45).
6
 At follow-up visits patients with BBL reported more pain, however, the 
differences were not statistically significant when compared to the no BBL group 
(p=0.16).
6
 Additionally, a second report found no difference in pain and symptoms for 
patients with ACL injury and concomitant BBL compared to patients with ACL injury 
without BBL.
23
 Patients were given three patient reported outcome instruments (PROs): 
the Knee Injury and Osteoarthritis Outcome Scores (KOOS) pain subscale, the KOOS 
symptom subscale and the Short-Form (SF)- 36 scale; and the results did not show higher 
scores on the PROS for patients with BBL.
23
    
 The results of these studies indicate there is inconsistent evidence regarding the 
effects of BBL on pain and function for patients with AKLI. Inconsistencies may exist as 
the effects of BBL on pain and function may be relative to the severity of the BBL.  The 
benefits of employing a BBL severity classification system may provide insights to 
determine if there are in fact differences in pain and function pre-operatively for patients 
with AKLI.  
14 
 
The Problem 
 The consequences of BBL and the suspected articular cartilage injury overlying 
these lesions require careful consideration when considering the management of AKLI. 
For example, numerous researchers have proposed changes in pre- and post-operative 
care, such as a delay in surgical intervention and/or weight bearing status prior to surgical 
intervention in order to allow the BBL and associated articular cartilage damage to 
resolve and heal.
16, 24, 49, 63, 71, 84
  A delay in weight bearing status has been recommended 
for patients with large or severe BBL in order to allow the bone and articular cartilage to 
heal, preventing further damage such as the development of PTOA.
63, 71, 84
 However, at 
this time these recommendations are based on hypothetical claims and prospective 
studies and randomized control trials to elucidate these phenomena have not been 
performed. Therefore, the identification of a biomarker that can differentiate between 
patients with and without BBL and between differing BBL severities is necessary to 
begin longitudinal investigations for these hypothetical claims. Additionally, the 
inclusion of the severity classification system may elucidate differences in self-reported 
pain and function for patients with AKLI and associated BBL. 
Purpose 
 There were 4 purposes of this dissertation. The first purpose was to determine the 
inter and intraday reliability of sCOMP in a physically active cohort. The second purpose 
was to document the stability of sCOMP in collegiate athletes during athletic 
participation and following AKLI. The third purpose was to determine if differences in 
sCOMP levels exist for patients following AKLI with and without BBL, and when 
compared according to BBL severities. The fourth purpose was to determine if 
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differences in self-reported pain and function exist for patients following AKLI with and 
without BBL, and when compared according to differing BBL severities. These studies 
were designed to address the following aims: 
1. To determine the inter and intraday reliability of sCOMP in a non-elite, physically 
active cohort. 
2. To document the stability of sCOMP over the duration of an athletic season and to 
determine if differences are present following AKLI.  
3. To determine if differences in sCOMP levels exist between patients with BBL and 
without BBL following AKLI. 
4. To determine if differences in sCOMP levels exist when patients are compared 
according to differing BBL severities following AKLI.  
5. To determine if differences in self-reported pain and function exist between 
patients with BBL and without BBL. 
6. To determine if differences in self-reported pain and function exist when patients 
are compared according to differing BBL severities following AKLI. 
Overview 
 The methods, results, discussion, limitations and conclusions for each of the six 
aims are presented in the following sequence. Chapter 2 summarizes the inter and 
intraday reliability of sCOMP in a non-elite, physically active cohort. Chapter 3 
summarizes the stability of sCOMP in an elite group of athletes over the duration of a 
soccer season and following AKLI. Chapter 4 summarizes the differences in sCOMP in 
patients with and without BBL, and for differing BBL severities. In addition, Chapter 4 
summarizes the differences in self-reported pain and function for patients with and 
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without BBL, and for differing BBL severities. Finally, Chapter 5 summarizes the 
findings from each of the studies and future research implications. 
Operational Definitions 
For the purposes of these studies, the following definitions will be used: 
1. Acute knee ligament injury (AKLI): An injury where one or more of the intra-, or 
extra-articular knee ligaments are sprained and the injury is documented via MRI. 
2. Bone bruise lesion (BBL): Increased signal intensities on T2-weighted images. 
3. Patient reported outcome instruments (PROs): Survey instruments used to assess 
patient oriented outcomes such as pain, function and health related quality of life 
following ALKI. 
4. Lower extremity surgery: Any type of invasive surgical technique that was 
performed to the articular joints of the lower extremity. 
5. History of surgery: Any type of invasive surgical technique that was performed to 
the upper or lower extremity articular joints, or any other musculoskeletal 
surgery. 
6. Skeletal maturity: Complete closure of the epiphyseal plates of the femur and the 
tibia assessed using standard anterior/posterior and lateral radiographs confirmed 
by an orthopaedic surgeon. 
Assumptions 
The primary assumptions for this dissertation were the following: 
For Chapter 2: 
1. The subjects recalled their medical history correctly and had no history of lower 
extremity surgery. 
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For Chapter 3: 
1. Subjects participated in the Spring 2010 soccer season. 
2. Subjects answered the PROs to the best of their abilities. 
3. The medical records that were reviewed were up to date and contained the correct 
previous medical history. 
For Chapter 4: 
1. Subjects recalled their medical history correctly and had no history of surgery or 
severe knee ligament injury. 
2. Subjects recalled their date of injury correctly. 
3. Subjects answered the PROs to the best of their abilities. 
4. Subjects did not have rheumatoid arthritis. 
5. The surgeons viewing the articular cartilage overlying the BBL understood the 
classification system that was employed. 
Delimitations 
The primary delimitations of this dissertation are the following: 
For Chapter 2: 
1. Subjects were males and females between the ages of 18 -50. 
2. Subjects had no history of severe knee ligament injury. 
3. Subjects had no history of lower extremity surgery. 
4. Subjects were considered physically active as qualified by a 6 or higher on the 
NASA physical activity scale. 
For Chapter 3: 
1. Subjects were males and females between the ages of 18-30. 
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2. Subjects were considered physically active as qualified by participating in NCAA 
Division I soccer. 
For Chapter 4: 
1. Subjects were males and females between the ages of 13-50. 
2. Subjects had no history of severe knee ligament injury. 
3. Subjects had no history of surgery. 
4. Subjects were skeletally mature. 
5. Subjects had an MRI and had visited the physician within four weeks of their 
injury. 
6. Subjects were considered physically active as qualified by a score of 8 or higher 
on the Tegner Activity Scale. 
Limitations 
For Chapter 2:  
1.  Subjects were included if they had a history of upper extremity surgery. 
For Chapter 3: 
1. Subjects were included if they had a history of injury or surgery. 
2. Data regarding the musculoskeletal injuries that were treated prior to the Spring 
2010 soccer season were retrospectively collected. 
3. Pertinent medical history data were retrospectively collected. 
For Chapter 4: 
1. A single radiologist measured the volume of the BBL and determined the severity 
of each lesion. 
2. Multiple surgeons viewed and scored the articular cartilage overlying the BBL.  
19 
 
3. Injuries to the ACL, PCL and MCL were included in this research study. 
4. Multiple MRI machines were used during this research study. 
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Table 1.1: Bone Bruise Severity Classification Systems. 
Classification 
System 
Type I Type II Type III 
Lynch et al.
59
 A loss of signal 
intensity on short 
TE images which 
are most often 
located within the 
medullary space of 
the bone, usually 
involving the 
epiphyseal and 
metaphyseal regions 
without interruption 
of the cortex. 
A loss of signal 
intensity on short 
TE images which 
are associated with 
an interruption of 
the black cortical 
line. 
A more profound 
signal loss than that 
of Type I or Type II 
lesions, which are 
often restricted to 
the region of bone 
immediately 
adjacent to the 
cortex without 
cortical interruption. 
 
Costa-Paz et al.
18
 
 
Diffuse signal with 
change in the 
medullary 
component, often 
reticular and distant 
from the subjacent 
articular cartilage. 
 
Localized signal 
intensity with 
contiguity to the 
subjacent articular 
surface. 
 
A disruption or 
depression of the 
normal contour of 
the cortical surface. 
Definitions of the Lynch et al., and Costa-Paz et al. classification systems taken from 
their respective manuscripts.
18, 59
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Table 1.2: Articular Cartilage Injury Severity Classification Systems for Overlying 
Articular Cartilage Injury Associated with Bone Bruise Lesions. 
 
Classification 
System 
 
Grade 0 
 
Grade I 
 
 
Grade II 
 
Grade III 
 
Grade IV 
Brittberg and 
Winalski
10
 
Normal 
cartilage 
appearance. 
Softening of 
the articular 
cartilage. 
Fibrillation 
of the 
articular 
cartilage. 
Fissuring 
of the 
articular 
cartilage. 
Full-
thickness 
defect with 
exposed 
subchondral 
bone. 
 
Johnson et 
al.
41
 
 
Normal 
cartilage 
appearance. 
 
Normal 
appearance 
with 
softening on 
probing. 
 
Fissuring or 
cracking 
along with 
softening. 
 
Fibrillation 
and 
softening. 
 
Overt 
chondral 
fracture or 
indentation. 
Definitions of the Brittberg and Winalski and Johnson et al. classification systems were 
taken from their respective manuscripts.
10, 41
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Figure 1.1: A figure depicting images of the individual Costa-Paz classifications
18
 for 
bone bruise lesions.  
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Figure 1.2: A figure depicting the volumetric measuring technique of Roemer and 
Bohndorf.
81
 
Step 1: Measuring plane (a) and (b) Step 2: Measuring plane (c) 
  
Using the image with the largest amount of 
signal intensity in the coronal plane, a 
straight line (a) will be drawn from the most 
peripheral margins of the area. A second line 
(b) will be drawn bisecting line (a) to define 
the second plane. 
 
Using the sagital images, a straight line will 
be drawn to determine the third plane. 
 
Images and definitions from: Roemer FW, Bohndorf K. Long-term osseous sequelae after 
acute trauma of the knee joint evaluated by MRI. Skeletal Radiol. 2002;31(11):615-623. 
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Chapter Two: Determination of the Inter and Intraday Reliability of Serum Cartilage 
Oligomeric Matrix Protein in a Physically Active Population 
Introduction 
 Cartilage oligomeric matrix protein (COMP) is a protein primarily identified in 
articular cartilage.
32, 68, 80
 Elevations of this biomarker have been identified in patients 
suffering from knee osteoarthritis (OA), a chronic articular cartilage degradation disease, 
when compared to healthy controls.
14, 15, 25, 43, 70, 89, 100
 In addition, synovial fluid and 
serum elevations of this biomarker have been documented in patients who suffer acute 
knee ligament injury (AKLI), such as anterior cruciate ligament (ACL) rupture.
19, 47, 58
 
The basic assumption is that these elevations are associated with articular cartilage 
damage, not ligament injury. However, documentation of concomitant injuries such as 
bone bruise lesions (BBL) and associated articular cartilage injury was not reported in 
these studies.
19, 47, 58
  
 An estimated 80% of MRI confirmed ACL ruptures have documented 
concomitant BBL.
59, 84, 90, 94
 Often these lesions are not associated with visible articular 
cartilage injury at the time of MRI and surgical intervention.
49, 66
  However, biopsies of 
the overlying articular cartilage indicate degeneration of the chondrocytes and substantial 
damage to the superficial matrix.
24, 41
 Therefore, COMP may be a useful biomarker to 
better understand the articular cartilage damage that is associated with BBL for patients 
who suffer AKLI.
24
  
 In order to further investigate the usefulness of COMP as a biomarker for acute 
articular cartilage damage, the reliability of this measure must be documented. 
Determination of inter and intraday reliability measures is necessary to ensure that this 
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marker is clinically applicable for future research studies. The purpose of this study was 
to determine the inter and intraday reliability of serum (sCOMP) in a healthy, physically 
active cohort.  
Methods 
Design 
 A repeated measures reliability design was employed for this study. The 
independent variable was time (time 1= T1, time 2= T2, time 3=T3) and the dependent 
variable was sCOMP.  
Population 
 A volunteer sample of 23 physically active subjects (4 males and 19 females; age: 
27.2+3.8 years; height: 168.6+6.3cm; weight: 150.6+31.4 kgs) volunteered to participate. 
Subjects were included if they had no history of lower extremity surgery and no history 
of lower extremity injury within the last 3 months. Subjects were considered physically 
active if they scored a 6 or higher on the NASA Physical Activity Status Scale.
102
 A score 
of 6 represents heavy aerobic exercise in the form of either running 6 to 10 miles a week 
or walking 7 to 13 miles per week.
102
 Subjects maintained their usual daily activities 
while participating and hourly documentation logs were collected while the subjects were 
enrolled. This study was approved by the University of Kentucky Institutional Review 
Board and approved informed consent was obtained from the subjects prior to 
participation in our study. 
Procedure 
 A total of three serum collections were performed on two separate days. To 
determine the interday (between day) reliability, subjects reported to the laboratory once 
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in the morning (T1) and approximately 7 hours later on the same day (T2). To determine 
intraday reliability (within day), subjects reported to the laboratory the morning after (24 
hours) the first draw (T3).  
 Upon arrival, each subject was asked to remain seated at a table for 30 minutes 
prior to data collection based on the recommendations of Andersson et al.
2
 and 
Mundermann et al.
69
 Following 30 minutes of rest, a maximum of 10ccs of blood was 
collected from the antecubital vein in a red top safety tube following standard operating 
procedures for venipuncture. 
 Enzyme-linked immunosorbent assay 
 Immediately after serum collection, the blood was placed on ice and transported 
for separation. After clotting for 30 minutes at room temperature, sera were separated in a 
centrifuge at 4˚C at 2000g for 15 minutes, placed in labeled aliquots and stored in a -80˚C 
freezer. Once all samples were collected, sCOMP concentrations were determined using 
a commercially available, competitive enzyme-linked immunosorbent assay (ELISA) kit 
(IBL Euro-Diagnostica, Malmo, Sweden). Serum COMP values are expressed as ng/mL. 
The average intraassay coefficient of variance (CV) of all controls was 2.8%, the average 
interassay CV of all controls was 2.1% and the average CV of all samples was 2.5%. 
Statistical Analysis 
 Descriptive statistics (means ± standard deviations) for each test session were 
calculated. Inter and intraday reliability were estimated using intra-class correlation 
coefficients (ICC2,1). A total of 20 participants’ data were used to calculate interday 
reliability (T1 vs. T3). A total of 23 participants’ data were used to calculate intraday 
reliability (T1 vs. T2). Standard error of measurement (SEM) was also calculated for 
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each correlation. ICCs were interpreted as weak if they were less than 0.40, moderate if 
between 0.41 and 0.69 and values of more than 0.70 were interpreted as strong.17 Within 
day and between day minimal detectable change (MDC) values were also calculated 
using the inter and intraday reliability and SEM data collected during each session. MDC 
values were calculated with a 95% level of confidence using the formula SEM * 1.96 
*√2.4, 104 All statistical analyses were performed using PWAS software, version 18.0 
(Somers. NY).  
Results 
 The mean sCOMP value (±standard deviation) for T1 was 1287.44 (±205.70) 
ng/mL, for T2 was 1292.90 (±228.00) ng/mL and for T3 was 1270.15 (±213.60). The 
ICC for both the interday (0.76) and intraday (0.74) were both interpreted as strong. The 
interday 95% MDC value (SEM 105.3) was 292 ng/mL and the intraday 95% MDC 
(SEM 154) was 320 ng/mL. 
Discussion 
 To our knowledge we were the first to document the inter and intraday reliability 
of sCOMP in a healthy, physically active cohort with no history of lower extremity 
surgery or acute lower extremity injury within the last three months. The results of this 
investigation indicate strong inter and intraday reliability for sCOMP in a young, 
physically active cohort. To provide a more comprehensive interpretation of our 
reliability values, comparisons of these findings to those that have been previously 
published are made. 
 Several studies have reported temporal patterns for sCOMP. For example, Vilim 
et al.95 conducted a study to verify the ELISA they used was sensitive to changes 
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overtime in sCOMP in multiple populations. As a subcomponent of their larger study, the 
authors reported that intersession variability was insignificant between days.
95
 
Specifically, the authors collected sCOMP over a period of six days in five volunteers 
with no obvious joint pathology.
95
 However, the specific variability of sCOMP was not 
reported as the data were presented in a line graph figure. Our interpretation of their 
graph was that the variability of the five volunteers did not differ more than 1 µg/mL. 
Notably, no documentation of participant demographics (age, gender, past medical 
history) were provided.
95
 These previous results in addition to the results within this 
study indicate sCOMP levels are stable and reliable between days in healthy populations. 
 The timing of data collection for sCOMP can be influenced by food intake. In 
addition, Vilim et al.
95
 also reported significant differences in time point one (morning 
fasting sample) and time point two (2 hours after lunch) in four of the 20 subjects that 
participated in their research study. For the remaining 16 subjects in their research study, 
no variation in the serum samples between the time points was identified.
95
  From the 
results of their investigation, a fasting, morning serum sample was recommended for 
collection in clinical research studies as it was concluded that the differences noted for 
the 4 individuals was related to food consumption.
95
 While this is a good 
recommendation it should be noted that the results of this study indicate strong intraday 
reliability, where the subjects were allowed to eat a non-regimented meal prior to each of 
the testing sessions (breakfast and lunch). 
 Diurnal variation of sCOMP has been documented in patients with OA and 
rheumatoid arthritis during a 24 hour observational study.
1, 46
 The results of a 24 hour 
observational study where patients with OA and rheumatoid arthritis had serum collected 
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every four hours indicated no significant changes in sCOMP levels throughout the 
waking hours.
1
 Patients that participated in both groups had regulated exercise regimens, 
scheduled meals and scheduled bed times.
1
 For patients with OA, the results of the 
investigation revealed no significant changes in sCOMP between 09:00 and 21:00.
1
 
However, the results of the study did reveal a significant decrease in sCOMP levels at 
05:00 (p<0.03).
1
 For patients with rheumatoid arthritis, no significant changes were 
observed between 08:00 and 20:00.
1
 In addition, a significant decrease in sCOMP was 
noted at 04:00 (p<0.001).
1
 The results of this study indicate sCOMP levels remain 
consistent during the waking hours, indicating sCOMP levels can be collected throughout 
the day for either clinical and or research purposes.
1
 Therefore, based on the results of 
this study and our study, the variation in sCOMP across the day is insubstantial.  
 A study conducted by Kong et al.
46
 reported diurnal variation in sCOMP in a 
cohort of patients with OA. The results of their clinical laboratory investigation revealed 
significant differences in sCOMP levels measured between the time before arising from 
bed (T0) and 1 hour after rising from bed (T1, p<0.001); between T0 and 4 hours after 
arising from bed (T2, p<0.001); and between T0 and 12 hours of daily activity (T3, 
p<0.01).
46
 It must be noted the authors reported they did not allow the participants to 
remain seated for more than 30 minutes at a time during study participation; the 
collection at T0 was obtained while the patients remained supine after awakening from 
the previous night’s rest and subjects were encouraged to engage in activities of daily 
living throughout the study duration.
46
  The significant differences in sCOMP levels 
between each of the time points may be due to the fact that the T0 sample was collected 
following rest and the other samples were collected following activity.
46
 Based on the 
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recommendations of Andersson et al.
2
 and Mundermann et al.
69
, 30 minutes of rest prior 
to serum collection is necessary to ensure elevations in sCOMP levels are not due to any 
moderate exercise, such as walking to the data collection site. However, it must be noted 
that the results reported by Kong et al.
46
 were published at the same time as Mundermann 
et al.
69
 and Andersson et al.
2
; therefore, they did not include this recommendation in their 
methodology. Based on these previous recommendations, the subjects were required to 
remain seated for 30 minutes prior to serum collection. The addition of this resting time is 
necessary in order to provide the most valid results of sCOMP levels.  
 The amount of physical activity each of the subjects engaged in while 
participating in this study was not controlled for. Also, the subject’s meal times were not 
regulated, as the subjects were encouraged to engage in their normal activities of daily 
living while participating our research study. Therefore, these results indicate this 
biomarker is reliable even when the subjects are not in a research laboratory environment 
where exercise, meal times and sleeping habits are regulated.
1, 46
  
Limitations 
 This study is not without limitations. In order to be included in this research 
investigation, the subjects had to have no history of lower extremity surgery and no 
current acute lower extremity injury. Subjects were not given a physical examination or 
radiographic examination prior to subject inclusion. Therefore, we were unable to verify 
each of the subjects were free of joint damage, such as OA.  However, these subjects 
were relatively young and reported no history of serious joint injury. Therefore, it is 
unlikely that substantial knee cartilage degradation had occurred in any of our 
participants. 
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Conclusion 
 These results indicate strong inter and intraday reliability for sCOMP values in a 
healthy, physically active cohort with no history of lower extremity surgery. The strong 
reliability of this measure demonstrates serum samples can be collected throughout the 
day for future clinical research studies.
1
 In addition, the stability of this marker further 
indicates increases in sCOMP levels following AKLI are due to injury and are not 
associated with diurnal variation for a population without disease history. Our 95% MDC 
values suggest a change in sCOMP levels of 290-320 ng/mL in an injured population 
represents a meaningful change which exceeds the variability associated with the 
measure. Future research studies are needed to further investigate the magnitude of 
change in this biomarker for patients with acute articular cartilage damage to determine 
its appropriateness for use in this population and for varying degrees of articular cartilage 
severity. 
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Chapter Three: Longitudinal Documentation of Serum Cartilage Oligomeric Matrix 
Protein and Patient Reported Outcomes in Collegiate Soccer Athletes over the course of 
an Athletic Season and in the Occurrence of Injury 
Introduction 
 It has been theorized that continuous, intense physical activity can cause the 
development of primary osteoarthritis (OA) in elite athletes.12, 48 Primary OA is 
characterized by irreversible joint destruction such as cartilage degradation, osteophyte 
formation and joint space narrowing,93 and causes pain, loss of function, activity 
limitations and participation restrictions in the millions of individuals each year.2, 11, 25, 26, 
96 There has been speculation regarding how articular cartilage responds to increases in 
activity level and determination of the levels related to articular cartilage damage due to 
intense physical activity is unclear.30 It has been hypothesized that sports that include 
rapid acceleration and deceleration moments, continuous training where the joints sustain 
high impacts and athletes that compete at elite levels for an extended period of time are at 
an increased risk of developing OA.12, 86 However, it is unknown to what extent the 
amount, types and intensity of exercise is detrimental to the articular cartilage in the 
human joint.30, 86At this time there are limited tools available to prospectively investigate 
the relationship between the early stages of degenerative joint disease, such as articular 
cartilage degradation and athletic participation, and whether or not biomarkers can 
facilitate the understanding of these processes. 
 Described as an instrument to measure the progress of a disease or the effects of a 
treatment on disease progression, biomarkers may serve as a tool to elucidate the effects 
of exercise on cartilage degradation and the eventual development of primary OA.67 A 
biomarker for cartilage degradation, known as serum cartilage oligomeric matrix protein 
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(sCOMP), is a non-collagenous protein identified in synovium, ligamentous tissue, 
tendon, meniscus and primarily articular cartilage.
15, 21, 27, 32, 68, 73, 80, 85
 Serum COMP 
levels are elevated following intense exercise
44
 and are elevated in subjects who 
participated in less strenuous forms of physical activity.
70, 73, 75
 
 Several studies have investigated changes in sCOMP during exercise. For 
example, in healthy subjects that participated in moderate walking exercises, marathons 
and ultra-marathons, there was an increase in sCOMP levels following activity.
44,70, 73
  
Serum COMP levels have been documented to return to baseline levels thirty minutes 
following a moderate walking exercise
70
 and after a longer period of time for more 
intense exercise.
44
 Following a marathon, sCOMP levels returned to baseline 24-48 hours 
following the race and for an ultra-marathon, sCOMP levels returned to baseline 6 days 
following the race.
44, 73
 Therefore, elevated levels of sCOMP as a result of physical 
activity may indicate that this biomarker may be useful in better understanding the 
relationships between exercise and articular cartilage changes. 
 It has been reported that elite level athletes who participate excessively in high 
impact sports for an extended period of time have a higher risk for developing primary 
OA.
86
 However, there are no prospective, longitudinal studies investigating the effects of 
continuous, intense physical activity over time on sCOMP. Therefore, to further 
investigate sCOMP as a biomarker for cartilage damage induced by exercise, it may be 
useful to prospectively study elite level athletes who participate in high impact sports. 
Documentation of the stability of this marker over the duration of an athletic season, 
rather than one bout of exercise, is needed for further investigation of the effects of 
exercise on articular cartilage. In addition, two patient reported outcome instruments 
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(PROS) to document self-reported function and knee related symptoms throughout the 
duration of the season were collected. These PROs were used to provide additional 
information that might explain changes in sCOMP levels such as decrease in function, or 
an increase in pain or knee related symptoms. 
 Elevated levels of COMP have also been reported following acute knee injury.
19, 
47, 58
 Serum and synovial fluid COMP levels in knee injured patients were elevated 
compared to controls, however, the documentation of associated concomitant injuries was 
not provided.
19, 47, 56
 In addition to documenting the stability of this biomarker in elite 
soccer athletes, we also aim to document changes in sCOMP following AKLI with or 
without BBL. This investigation will be the first to prospectively document changes in 
sCOMP in an uninjured cohort that is subsequently injured following activity. 
 The primary purpose of this investigation was to document the stability of 
sCOMP in collegiate soccer athletes during a spring soccer season. In addition, we aimed 
to document patient reported outcomes assessing pain and function related to the knee 
joint, using two separate PROs. It was hypothesized that sCOMP levels and PRO scores 
would remain stable over the duration of the spring soccer season. The secondary purpose 
is to document changes in sCOMP levels following acute knee injury. It was 
hypothesized sCOMP levels would be increased following AKLI compared to baseline 
levels. 
Methods 
Design 
 A prospective, repeated-measures design was employed for the primary aim of 
this study.  
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Population 
 A volunteer sample of 29 NCAA Division I soccer athletes (18 males, 11 females; 
age: 19.6+1.2years; height: 177.8+7.4cm; weight:73.8+10.2kgs) participated in this 
research study. Subjects were included if they were actively participating in the spring 
soccer season. Subjects were excluded if they were not participating in soccer related 
activities due to injury. Informed consent was obtained from the subjects participating in 
the study. This study was approved by the Institutional Review Board at the University of 
Kentucky. 
Procedure 
 Subjects reported for data collection at three time points (pre- (T1), mid- (T2) and 
post-season (T3)) over the duration of their spring soccer season (February 2010-May 
2010). Upon arrival, each subject was asked to remain seated for 30 minutes. It is 
recommended that subjects remain seated prior to serum collection in order for serum 
levels to return to baseline following any moderate exercise such as walking to the data 
collection site.
2, 69
 During the 30 minutes of rest, the subjects were asked to complete two 
PROs. (IKDC, Lysholm). Once the subject had been seated for 30 minutes and both 
PROs were completed, a maximum of 10ccs of blood was collected from the antecubital 
vein.  
 In the event a subject suffered an AKLI while participating in our research study, 
they were included in the secondary aim of our research investigation. Per our approved 
protocol, following AKLI, subjects were evaluated by an orthopaedic team physician 
within 72 hours. Serum was collected at the time of physician evaluation (Time of 
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Injury). If surgery was warranted, serum was collected immediately preceding surgical 
intervention (Time of surgery).  
 Enzyme-linked immunosorbent assay 
 The blood was immediately placed on ice and transported for separation. After 
clotting for 30 minutes at room temperature, sera was separated and stored in a -20˚ C 
freezer and eventually transported into a -80˚ C freezer until assayed. Once all samples 
were collected, sCOMP concentrations were determined using a commercial enzyme-
linked immunosorbent assay (Euro-Diagnostica, ALPCO, Salem, NH). Serum COMP 
values are expressed as ng/mL. The average intra-assay coefficient of variance (CV) of 
all controls was 1%, the average intra-assay CV of all samples was 1% and the average 
inter-assay CV of all controls was 4%. 
 Patient reported outcomes 
 Subjects completed two PROs for this study, the IKDC and the Lysholm. These 
were used to assess function and symptoms related to the knee and were completed by 
each subject at each of the time points. The IKDC is a valid and reliable PRO that is used 
to measure knee symptoms, level of function and sports activity in patients following 
knee injuries.
31, 40
 Higher scores represent patients with higher levels of function and 
fewer self-reported knee symptoms.
31, 40
 A change of ±9 points is required to indicate a 
clinically meaningful change in the patient’s knee symptoms.40 The IKDC has acceptable 
internal consistency and test-retest reliability.
39
  
 The Lysholm knee scale measures eight condition specific domains for the 
knee.
60, 92
 These domains include: limping, use of supporting device, stair climbing, 
squatting, walking, locking, instability and pain.
60, 92
 The Lysholm is scored from 0 to 
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100, where a score of 95 to 100 is excellent, 89 to 94 is good , 65 to 83 is fair and <65 is 
a poor.
45
 A minimal detectable change (MDC) for the Lysholm is ±8.9 points.
8
 For 
patients with chondral and ACL injuries, the Lysholm has acceptable internal consistency 
and  test-retest reliability.
8, 45
   
Statistical Analysis 
 For the primary aim of this research study, descriptive statistics (Mean ± Standard 
Deviation (SD)) for sCOMP and PROs for each time point were calculated. The 
independent variables were time and gender. The dependent variables were sCOMP 
values and scores on two PROs (Lysholm, International Knee Documentation Committee 
(IKDC)). Separate linear mixed models analyses were used to determine sex by time 
differences in each of the dependent variables (sCOMP, IKDC, Lysholm) for each of the 
time points (T1, T2, T3). Paired-sample t-tests were used to explain significant interactions 
or main effects.  Hedge’s g effect sizes33 with 95% confidence intervals (CI) were 
calculated to examine the magnitude of change over time for each of the dependent 
variables. Calculated effect sizes were interpreted as weak if they were less than 0.40, 
moderate if between 0.41 and 0.69 and values > 0.70 were interpreted as strong.
17
 Alpha 
was set a priori at p<0.05.   
 The secondary aim of our study was to document changes in sCOMP following 
acute knee injury. A cohort of nine uninjured females was used to provide reference 
sCOMP values for the T1 and T2 time points. For the uninjured cohort, 95% CI 
(SE*1.96) were calculated for T1 and T2.  
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Results 
 A total of eight subjects (3 females and 5 males) had a history of lower extremity 
surgery and none of the subjects had a history of upper extremity surgery; with the most 
recent surgical procedure occurring in the summer of 2009. Other pertinent medical 
history for participating subjects included patellar dislocation, patellar fracture, tibial 
stress fractures, wrist fracture, ankle fracture and clavicle fracture. Following a review of 
the medical records, seven athletes that participated in the research study were treated 
during the spring 2010 soccer season for common musculoskeletal injuries such as a 
quadriceps strain, Iliotibial tendonitis, ankle sprains, medial collateral ligament sprains, 
and spondylolisthesis. All subjects that participated with a history of surgery were 
medically cleared to participate in soccer activities as determined by an orthopaedic 
surgeon and a primary care physician. No ongoing or resolving musculoskeletal injuries 
were recorded in subjects that were enrolled into the study at the time of physical exam. 
All subjects that were treated for musculoskeletal injuries during the spring 2010 soccer 
season were included if they were actively participating in soccer activities during the 
data collection sessions. 
 Figure 3.1 depicts the total number of subjects that participated at each data 
collection session and the total number of sCOMP samples collected. Missing data points 
were attributed to: a) the inability of the phlebotomist to collect a sample from the 
subject, b) sample processing error, c) removal from the team, or d) severe knee injury at 
time of data collection.  Figure 3.1 also depicts the time lapse between each of the data 
collection sessions. If sCOMP samples were not available for the analysis, the PRO 
scores for those subjects remained in the analysis for each of the time points. 
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Serum COMP Values 
 Descriptive statistics for each of the time points can be found in Table 3.1. A 
graph of the course of sCOMP for each of time points can be found in Figure 3.2. There 
was no significant sex by time interaction for sCOMP (p=0.44). There was no significant 
effect for sex (p=0.09). There was a significant effect of time on sCOMP levels 
(p<0.001), with significant increases between T1-T2 (p<0.001), T1-T3 (p=0.002), but not 
for T2-T3 (p=0.08). Calculated Hedge’s g effect sizes and 95% CIs for sCOMP were 1.00 
(CI: 0.43, 1.57) for T1 vs T2 and 0.63 (CI: 0.02, 1.23) for T1 vs T3.  One of these effect 
sizes was interpreted as strong (1.0) and the second effect size was interpreted as 
moderate (0.63), and the associated 95% CI for both do not encompass zero.  
sCOMP Minimal Detectable Change  
 We calculated minimal detectable change (MDC) values using intersession 
reliability via an intraclass correlation coefficient (ICC) and standard error of 
measurement (SEM). A total of 18 subjects had sCOMP values for all three data time 
points and these values were used to calculate MDC scores. MDC scores were calculated 
with a 95% level of confidence using the formula SEM * 1.96 * √3.4, 104 Intersession 
reliability over the three collection time points was ICC=0.61 (SEM=136.9 ng/mL). The 
MDC value for sCOMP was 464.6 ng/mL. 
Patient Reported Outcomes 
 Descriptive statistics for each of the PROs can be found in Table 3.1. There was 
no significant sex by time interaction for either the Lysholm (p=0.52) or the IKDC 
(p=0.16). There was no significant effect for sex for either the Lysholm (p=0.10) or the 
IKDC (p=0.25). A significant effect for time was noted for the Lysholm (p=0.04), with 
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significant increases between T1-T3 (p=0.03) and a trend for statistical difference between 
T2-T3 (p=0.06). A significant effect for time was noted for the IKDC (p=0.02), with 
significant increases between T1-T3 (p=0.02) and T2-T3 (p=0.04).  
 For the Lysholm, the effect sizes were -0.09 (CI: -0.64, 0.46) for T1 vs T2 and 
0.41  (CI: -0.15, 0.97) for T1 vs T3, with one effect size interpreted as weak and one effect 
size interpreted as moderate. Calculated effect sizes for the IKDC were 0.10 (CI: -0.44, 
0.64) for T1 vs T2 and 0.49 (CI: -0.08, 1.1) for T1 vs T3 with one effect size interpreted as 
weak and one effect size interpreted as moderate. However, caution must be used when 
interpreting these results as for each effect size, the 95% CIs did encompass zero. 
Injured Data 
 One female subject (age 19 years) suffered an AKLI during data collection. 
Interestingly, she suffered an AKLI 24 hours after the T2 data collection session and we 
were able to collect her time of injury serum one hour following her injury. Her sCOMP 
level T1 was 1208 ng/mL, T2 was 1844 ng/mL, at the time of injury was 1682 ng/mL, 
and time of surgery was 1068 ng/mL (Figure 3.3). Seven uninjured female subjects (age: 
19.7±1.1 years, mass: 66.2±10.3 kgs, height: 173.1±8.6 cms) were included to provide 
reference sCOMP values for the injured cohort.  The mean (±SE) sCOMP values for the 
uninjured cohort for the pre-season time point was 1269 (±64) ng/mL and for the mid-
season time point was 1364 (±74) ng/mL (Figure 2.3). As seen in Figure 3.3, the value 
for the case subject is within the 95% CI at baseline (T1), however, her sCOMP value 
falls outside the 95% CI at the midseason time point (T2). 
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Discussion 
 The purpose of this study was to document the stability of sCOMP levels and 
PRO scores in uninjured collegiate soccer athletes at three time points during a 
competitive athletic season. It was found that sCOMP levels and PRO scores increased 
over the duration of an athletic season. It was also demonstrated that an intersession 
MDC value of 464.6 ng/mL is necessary to identify significant changes that exceed the 
variability of the measure. In addition, this study documented sCOMP changes 
prospectively and following acute knee injury in one of the female soccer players. The 
injured subject’s sCOMP levels were significantly elevated the day prior to her ACL 
injury and after her injury, compared to baseline levels.  
Stability of sCOMP during elite physical activity 
 There are few published studies that report baseline levels for young, healthy 
athletes.
58, 85
 Previously reported levels of sCOMP for 6 healthy athletes with no history 
of joint disease or joint injury (ages 30±9) were 47µg/mL with a range from 10-109 
µg/mL.
58
 In addition, baseline levels have been reported using healthy blood donors ages 
20-65 and healthy children ages 1-20, where sCOMP levels were reported to be  
11.3µg/mL (1130 ng/mL) and 10.3µg/mL (1030 ng/mL) respectively.
85
 When 
interpreting sCOMP results, it is important to realize inter-study variation may be due to 
several factors including standards used for the ELISA, age, BMI, ethnicity and previous 
surgical intervention.
15, 43
 We believe it is imperative authors report these demographics 
to allow for proper interpretation of these data, particularly athletic populations who are 
likely to have had previous musculoskeletal injuries. 
42 
 
 This is the first study to report intersession MDC values for sCOMP levels in a 
healthy, physically active population over the duration of an athletic season. These 
findings indicate an alteration in sCOMP levels of 464.6 ng/mL is required to identify 
changes that exceed the variability of the biomarker over a three month athletic season.  
In addition, we have recently reported inter and intraday MDC values for a physically 
active cohort with no history of lower extremity surgery.
36
  These differences may be 
real, as subjects with a history of surgery were included in the present study but not in the 
prior Hoch et al. study. 
36
 Recent literature has hypothesized the use of sCOMP as a 
biomarker to elucidate the effects of acute articular cartilage injury and the development 
of preclinical posttraumatic osteoarthritis.
24
 The reported MDC values may be beneficial 
in future investigations of this relationship, which will allow comparison to determine 
meaningful changes that are associated with this measure.  
 This is the first study to report changes in sCOMP levels over the duration of an 
athletic season in healthy subjects. Previous research investigations have reported 
changes in sCOMP levels following single bouts of activity.
44, 69, 70, 73, 75
  The results of 
this study indicate a statistical difference in the increase in sCOMP levels between T1 
(1482.9±217.9 ng/mL) and T2 (1723.5±257.9 ng/mL, p=0.001) and T1 (1482.9±217.9 
ng/mL) and T3 (1624.7±231.6 ng/mL, p=0.002). In addition, there was a trend for a 
statistically significant decrease in sCOMP levels from T2 (1723.5±257.9 ng/mL) and T3 
(1624.7±231.6 ng/mL, p=0.08).  However, based on the calculated MDC value of 464.6 
ng/mL, differences of 241 ng/mL for T1-T2, 142 ng/mL for T1-T3 and 99 ng/mL for T2-T3 
are not clinically significant as they do not exceed the variability associated with the 
measure. At this time it is not exactly known whether or not changes following single 
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bouts of exercise are either indicative of an increase in cartilage matrix turnover or 
cartilage damage.
2, 44, 73
 The current findings show, while not clinically significant, there 
are increases in sCOMP levels over the duration of an athletic season in young, healthy 
athletes. Even though we measured changes over the three month period, we are unable 
to speculate whether or not these fluctuations were related to an increase in cartilage 
matrix turnover or matrix degradation. In addition, we are unable to determine the 
longitudinal effects of these fluctuations on overall articular cartilage health. Finally, we 
hypothesize there was a trend for decreasing sCOMP levels from T2-T3 due to a decrease 
of the amount of participation during the final four weeks of the season. Total time of 
participation data were not available to support this speculation; however, we do know 
that as the spring soccer season came to an end, the athletes participated in fewer practice 
sessions and games. Based on these results, future research studies are needed to 
investigate the influence participation on sCOMP levels in a physically active cohort. 
 The current findings indicate a statistical difference between time points for the 
IKDC and Lysholm. While these differences are important and documentation of change 
due to normal physical activity is important when employing PROs, it must be cautioned 
that these differences were not clinically significant based on previously reported MDC 
values. It has been reported a change of ±9 points for the IKDC and ±8.9 points for the 
Lysholm indicates a significant change in patient’s knee symptoms.8, 40  For the IKDC, a 
5.1 point difference between T1 (89.7±12.4) and T3 (94.8±6.1) and a 4 point difference 
between T2 (90.8±8.8) and T3 (94.8±6.1) are not large enough to indicate a clinically 
significant change in a subject’s knee symptoms. For the Lysholm, a 2.4 point difference 
between scores of T1 (92.4±8.4) and T3 (96.2±7.1) and a 4 point difference between T2 
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(92.3±10) and T3 (96.3±7.3) are also not sufficiently large to indicate clinically 
significant changes in the subject’s knee symptoms. Furthermore, recent literature has 
reported normative data for the Lysholm knee score in patients with normal knees.
9
 The 
average Lysholm score was 94 (range 43-100) for uninjured, normal participants.
9
  Our 
data are representative of this score, with scores ranging from 92 to 95 in our uninjured 
participants. The change in PRO scores did show that these athletes saw improvements in 
their knee joint health and function over the duration of the athletic season. 
Course of sCOMP following acute knee injury 
 Serum COMP levels were elevated in the injured subject at her second data 
collection time point, which occurred the day prior to ACL injury. We were surprised 
sCOMP was elevated, and at this time it is unclear if this elevation could potentially be 
an indicator of high joint load, and whether this would have any implication for the injury 
she sustained.
34
 One could speculate the increased levels of sCOMP at the mid-season 
data collection time point could signify an increased cumulative load on the knee joint 
over time; as the injured patient’s sCOMP level at the second time point was greater than 
the upper limit of the uninjured cohort (Figure 3.3). However, additional data are required 
to better understand the relationship between cumulative load and elevated sCOMP 
values.  
 The injured female soccer player had a Costa-Paz
18
 Type I concomitant bone 
bruise lesion documented on MRI. The location of the bone bruise on the femoral 
condyle was unique when compared to previous description.
18
 Costa-Paz 
18
 has described 
tibial plateau lesions are more prevalent for Type I classifications and the prevalence of 
femoral condyle lesions are associated with Type II and III classifications. The 
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implication of the location of injury is not clear but it has been reported that Type I and 
Type II classification are more likely to resolve and are less likely to present as 
postoperative lesions.
18
 Hence, the identification of biomarkers associated with 
subchondral lesions may provide additional information regarding damage prior to- and 
following injury.
24
  
 Our injured athlete’s sCOMP levels returned to below baseline (pre-season) at the 
time of surgery. The return to below baseline values was likely due to her pre-surgical 
rehabilitation plan. The rehabilitation plan consisted of ambulation in a locked brace with 
the knee in extension, with partial weight bearing and exercises to restore ROM, increase 
strength and control edema. Therefore, there was a significant decrease in weight bearing, 
which may have reduced the compressive forces on the articular cartilage. Future 
prospective investigation of these biomarker levels to assess diagnostic and prognostic 
efficacy is warranted.  
Limitations 
 The present study is not without limitations. First, subjects that participated in the 
study were not excluded based on prior medical history. For inclusion in our study, the 
subjects had to be participating in the 2010 spring soccer season and free of acute injury 
causing them to miss practice or games. Subjects with a history of injury, including 
anterior cruciate ligament knee reconstruction (ACLR) were included in our study. Since 
our aim was to determine the stability of sCOMP over time, we did not feel excluding 
subjects with past severe injury was necessary. Furthermore, both PROs we used were 
specific to the knee joint. Serum COMP is not specific to cartilage degradation at the 
knee joint. Therefore, the use of PROs for other joints, such as the Foot and Ankle 
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Ability Measurement (FAAM)
62
 or the Disabilities of the Arm, Shoulder and Hand 
(DASH )
37
 could have been employed to determine self-reported function for these joints. 
Finally, we did not control for participation in activities outside of soccer practice and 
soccer associated activities such as lifting and running.   
Conclusion 
 The present findings indicate that sCOMP levels do not remain stable in healthy, 
collegiate level soccer players over the duration of a soccer season. However, the 
difference between each of the separate time points was less than our calculated 
intersession MDC value of 464.6 ng/mL. These results imply that the effects of intense, 
continuous physical activity resulted in cartilage degradation as the result of 
microtraumatic injury or increased turnover, indentified as increased levels of sCOMP. In 
addition, change in PRO scores for the Lysholm and IKDC did not indicate any decrease 
in performance or function, or increases in pain. In contrast, the PROs indicated subjects 
were functioning at higher levels and were reporting near excellent knee joint health as 
the season progressed. Therefore, in our population sCOMP levels increased but 
potentially not at a level that is detrimental to articular cartilage health and not at a level 
that is clinically meaningful based on our MDC value. Future research investigations are 
warranted to further determine the relationship between these increased levels in sCOMP 
over the duration of an athletic season, cartilage degradation and a possible connection 
with primary OA development in athletes who participate in continuous, intense physical 
activity.    
 In addition, our study indicated sCOMP levels were elevated prior to injury, 
following injury and returned to baseline (pre-season) levels following a four week 
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period with limited weight bearing. Further study is required to better understand the 
relationship between sCOMP and cumulative load. Given sCOMP is a biomarker for 
cartilage degradation and our subject had a Costa-Paz
18
 grade I bone bruise lesion visible 
by MRI, future research should also investigate subchondral injury and identifiable 
biomarkers.  
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Table 3.1: Serum Cartilage Oligomeric Matrix Protein (sCOMP) Levels and Patient 
Reported Outcome Scores (Lysholm and International Knee Documentation Committee 
(IKDC)) for each of the Time Points (pre-season (T1), mid-season (T2) and post-season 
(T3)). 
Dependent Variable 
(Mean±SD)* 
Pre-season (T1) Mid-season (T2) Post-season (T3) 
sCOMP (ng/mL) 1482.9±217.9
†,ǂ
 1723.5±257.9 1624.7±231.6 
Lysholm     93.1±8.1
†
     92.3±10
†
    96.3±7.3 
IKDC     89.7±12.4
†
     90.8±8.8
†
    94.8±6.2 
 *: Differences are significant at p<0.05. 
†
: Significantly different from T3. 
ǂ
: Significantly different from T2. 
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Figure 3.1: Flow chart depicting subject participation, data loss, and time between data 
collection sessions. 
All men’s and women’s soccer 
athletes that consented to 
participate in our research 
study (n=29) 
1
st
 women’s data collection 
session (n=11) 
1
st
 men’s data collection 
session (n=18) 
2
nd
 women’s data collection 
session (n=9) 
2
nd
 men’s data collection 
session (n=16) 
3
rd
 women’s data collection 
session (n=6) 
3
rd
 men’s data collection 
session (n=12) 
6 weeks  
4 weeks  5 weeks 
6 weeks 
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Figure 3.2. The course of serum cartilage oligomeric matrix protein (sCOMP) at three 
different time points over an athletic season. 
 
Mean sCOMP values (±SD) at pre-season (T1), mid-season (T2), and post-season (T3) 
for the male and female soccer players.  
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Figure 3.3: Course of serum cartilage oligomeric matrix protein (sCOMP) in the injured 
female athlete compared to a representative female cohort. 
 
Serum COMP at pre-season, mid-season, time of injury and time of surgery in a soccer 
player who suffered an acute ACL rupture and Costa-Paz type I bone bruise, compared to 
the uninjured female players (mean±95% CI). 
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Chapter Four: Differences in articular cartilage damage, and self-reported pain and 
function for patients with acute knee ligament injury based on bone bruise lesion 
presence and severity 
Introduction 
 Bone bruise lesions (BBL) were first reported by Mink and Deutsch and were 
defined on T-1 weighted images as  traumatically involved geographic and non-linear 
areas of signal loss involving the subcortical bone.66 This investigation indicated that 
BBL were commonly associated with injuries to the anterior cruciate ligament (ACL), 
and that they are not visible on plain radiographic films.66  Numerous investigations have 
since confirmed the commonality of these lesions as BBL are present on an estimated 
80% of MRI confirmed ACL ruptures,84, 90, 94 and have also been documented following 
injuries to the posterior cruciate ligament (PCL),61 medial collateral ligament (MCL)65 
and posterolateral corner (PLC).28, 94  
 Numerous studies have proposed the modification of protected weight bearing to 
current rehabilitation protocols for patients with severe BBL prior to and following 
ligament reconstruction.16, 24, 50, 71  It is hypothesized that delayed weight bearing for 
patients with more severe BBL will prevent irreversible damage from occurring to the 
articular cartilage by allowing time for the lesion and bone to heal.24, 71 However, due to 
the lack of objective measuring tools available and the lack of use of severity 
classification systems, current rehabilitation protocols for patients suffering acute knee 
ligament injury (AKLI) do not account for severity of BBL nor account for the associated 
articular cartilage damage. The identification of a biomarker that can further elucidate the 
relationship between BBL severity and articular cartilage damage may be useful for 
understanding the effects of current rehabilitation protocols on these lesions,24 and a more 
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cost-effective solution to understanding the outcomes of these lesions. For a biomarker to 
be effective for diagnosing disease or monitoring disease progression, it must be sensitive 
to differences between healthy individuals and those with cartilage damage and among 
varying degrees of severity.
3, 14, 15
 For patients with AKLI, it has been hypothesized that 
serum cartilage oligomeric matrix protein (sCOMP) could be used as a biomarker to 
further investigate cartilage damage and metabolism.
24, 47
 
 Serum COMP, a cartilage degradation biomarker primarily identified in articular 
cartilage,
32, 47, 68, 72, 80
 and has been investigated as a prognostic and diagnostic indicator 
for osteoarthritis (OA).
22
 It has been proposed as a potential marker to monitor treatment 
effects following cartilage damage with the hope that cartilage protective therapies can 
delay further cartilage degeneration and prevent irreversible joint damage associated with 
OA.
93
 The results of a recent systematic review and meta-analysis indicated sCOMP is 
able to differentiate between patients with and without OA, and between different levels 
of knee OA severity as measured by the Kellgren/Lawrence scale.
35
 In addition, 
differences in synovial and sCOMP levels for patients with AKLI have been reported in 
the literature.
19, 47, 58
 Serum COMP levels in knee injured patients were elevated 
compared to controls.
47
 Furthermore, visible damage and histological changes of the 
overlying cartilage in patients with BBL have been reported.
16, 24, 41, 91
 During arthroscopy 
varying degrees of cartilage damage have been visualized, ranging from pristine 
cartilage, “dimpling” of the area, to softening, fissuring, fibrillation and defect.16, 41, 50 
Biopsies of the articular cartilage overlying acute BBL indicated degeneration of the 
chondrocytes.
41
 Furthermore, immunostaining for COMP of the articular cartilage 
overlying BBL demonstrated an increase of COMP in the superficial layer matrix, 
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indicating significant damage to the articular cartilage.
24
 Based on this available 
evidence, sCOMP is thought to be a viable biomarker to investigate outcomes following 
AKLI and associated articular cartilage injury.
24
 However, one limitation with the 
previous studies that investigated COMP levels following AKLI are that the 
documentation of associated concomitant injuries nor the severity of BBL were not 
provided.
19, 47, 58
 Since damage to articular cartilage is not evident on plain radiographs 
and often not evident on MRI or during arthroscopy, we have chosen to use BBL 
presence and BBL severity as an indicator of an area of articular cartilage that has 
sustained a high impact injury. Therefore, we must first determine if this biomarker is 
able to differentiate between patients with and without the condition of interest (BBL), 
and between differing severities of BBL before it can be employed in prospective, 
longitudinal investigations. 
 Finally, there is inconsistent evidence investigating the short term effects of BBL 
on pain and function in patients with AKLI with concomitant BBL. It has been reported 
that patients with acute ACL injury and BBL had greater reported pain and loss of 
function compared to patients without BBL.
42, 97
 In addition, these patients had an 
effusion for a longer period of time and took longer to achieve a nonantalgic gait 
compared to patients without BBL.
42
 In contrast, no significant differences in self-
reported pain scores between patients with and without BBL documented on MRI has 
been reported.
6, 23
    
 This evidence indicates that there are inconsistencies regarding the effects of BBL 
on pain and function for patients with AKLI.
6,23, 42, 97
 Inconsistencies may exist for 
several reasons and one reason may be that there is not a uniform measuring system to 
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assess the severity of these lesions. Hypothetically, the effects of BBL on pain and 
function may be relative to differing BBL severities.  The benefits of a BBL severity 
classification system may provide insights to determine if there are in fact differences in 
pain and function for patients with AKLI and concomitant BBL.   
 Therefore, the purpose of this study was to determine if differences in articular 
cartilage damage, and self-reported pain and function exist for patients with AKLI, based 
on BBL presence and severity. The purposes are four fold and are presented below, along 
with the null (Ho:) and alternative (Ha:) hypotheses. 
1. To determine if differences in sCOMP levels exist between patients with BBL 
and without BBL. 
 Ho: There will be no differences in sCOMP levels between patients with 
 and without BBL. 
 Ha: Patients with BBL will have higher sCOMP levels when compared 
 with patients without BBL. 
2. To determine if differences in sCOMP levels exist when patients are 
compared according to differing BBL severities. 
 Ho: There will be no differences in sCOMP levels when patients are 
 compared according to differing BBL severities. 
 Ha: Patients with more severe BBL will have higher sCOMP levels when 
 compared to patients with less severe BBL. 
3. To determine if differences in self-reported pain and function, as measured by 
patient reported outcomes (PROs), exists between patients with and without 
BBL. 
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 Ho: There will be no differences in self-reported pain and function for 
 patients with and without BBL. 
 Ha: Patients with BBL will have higher functional limitations and self-
 reported pain compared to those without BBL. 
4. To determine if differences in self-reported pain and function, as measured by 
PROs, exists when patients are compared according to differing BBL 
severities. 
 Ho: There will be no differences in self-reported pain and function for 
 patients with difference BBL severities. 
 Ha: Patients with more severe BBL will have more functional limitations 
 and self-reported pain compared to patients with less severe BBL. 
Methods 
Design 
 A cross-sectional study design was employed to determine if: a) differences in 
serum cartilage oligomeric matrix (sCOMP) levels exist between patients with BBL and 
without BBL following AKLI; b) to determine if differences in sCOMP levels exist when 
patients are compared according to differing BBL severities following AKLI; c) to 
determine if differences in self-reported pain and function, as measured by PROs, exist 
between patients with and without BBL; and d) to determine if differences in self-
reported pain and function, as measured by patient PROs, exist when patients are 
compared according to differing BBL severities following AKLI. The dependent 
variables were sCOMP values and scores on the PROs.   
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Population 
 A volunteer sample of 59 patients (gender: 32 males and 27 females, age: 
21.4±8.7 years, height: 174.6±9.6 cms, mass: 80.0±20.3 kgs, BMI: 25.4±5.2) were 
recruited at the University of Kentucky Orthopaedic and Sports Medicine Clinic. Patients 
were included if they had an AKLI (cruciate or collateral) confirmed on MRI. For the 
purposes of this study, the MRI, physician visit and data collection must have been 
obtained within four weeks from the date of injury. All patients were confirmed skeletally 
mature on plain radiographs, had no evidence of osteoarthritis development (Kellgren 
Lawrence score of 0), had no previous history of lower extremity surgery or severe knee 
ligament injury documented on MRI and were fluent in and able to read English. Patients 
were excluded if they were pregnant, a prisoner, or had diminished capacity to provide 
informed consent. Furthermore, patients were excluded if they had rheumatoid arthritis. 
This study was approved by the University of Kentucky Institutional Review Board 
(IRB). Informed consent was obtained from the participants prior to participating in the 
research study.  
Procedures 
 Following physician diagnosis and MRI confirmation of AKLI, patients were 
asked to participate in the research study. Once the patients reviewed and signed the 
informed consent document, they were asked to remain seated for 30 minutes prior to 
serum collection.
2, 69
 During the 30 minutes of seated rest, patients were asked to 
complete three PROs (International Knee Documentation Committee (IKDC, Appendix 
A), The Knee Injury and Osteoarthritis Outcome Score (KOOS, Appendix B) and the 
Short Form-12 (SF-12, Appendix C)). Once the patients had remained seated for 30 
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minutes, and all PROs were complete, a maximum of 10cc of blood was collected from 
the antecubital fossa. 
 Processing of serum 
 Following serum collection, the blood was allowed to clot for 30 minutes at room 
temperature. The serum was then separated in a refrigerated centrifuge at 4˚C, 2000g for 
15 minutes, placed in labeled aliquots and placed on ice. The aliquots were then 
transported to a -80˚C freezer for storage prior to the assays.  
 Bone bruise MRI assessment  
 All MRIs obtained for participating subjects were independently reviewed by one 
musculoskeletal radiologist in the University of Kentucky Division of Musculoskeletal 
Radiology. The radiologist documented: a) presence of BBL, b) number of BBL, c) 
location of each BBL, d) volume of each BBL and e) severity of each BBL. The 
radiologist was blinded to the patient’s clinical examination to eliminate bias. Each 
patient was classified according to a) the presence of bone bruise (BBL present, BBL 
absent) and b) severity of bone bruise (Costa-Paz classification (CPC)-I, CPC- II CPC-III 
and no bone bruise). In the event the subject had more than one BBL, they were classified 
according to the most severe lesion for data analysis. 
 Articular cartilage assessment 
 For patients who underwent surgical reconstruction of their injured ligament(s), 
visualization of the articular cartilage overlying the BBL lesions was documented. During 
the surgical intervention, the orthopaedic surgeon visualized the overlying articular 
cartilage and documented the damage to the overlying articular cartilage: normal, 
softening, fibrillation, fissuring, or defect. 
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Instrumentation 
 Patient reported outcomes 
 International Knee Documentation Committee (IKDC) 
 The IKDC is a valid and reliable tool that consists of questions that measure 
symptoms, level of function and sports activity in patients who suffer knee injuries.
40
 The 
patients are asked to check boxes that represent their ability to perform certain tasks or 
symptoms that best represent their given their knee injury. A higher score represents a 
greater level of function and lower level self-reported knee symptoms.
31, 40
 A minimal 
detectable change (MDC) of ±9  points must be calculated to demonstrate a clinically 
meaningful change in knee symptoms.
40
 The IKDC has high internal consistency 
(ICC=0.92) and high test-retest reliability (ICC=0.94).
40
 For the purposes of this study, 
the IKDC current pain score (0-10) was used to assess pain for this study. In addition, the 
IKDC current function score (0-10) and the overall IKDC score were used to assess 
function for this study. 
 The Knee Injury and Osteoarthritis Outcome Score (KOOS) 
 The KOOS tool is comprised of 5 domains which assess: pain (KOOS-P), 
symptoms (KOOS-S), function related to activities of daily living (KOOS-ADL), 
function related to sports and recreation (KOOS-SP) and quality of life (KOOS-QOL) 
related to the knee following joint injury.
83
 Each domain has a set of questions with five 
possible choices for the answer such as: never-rarely-sometimes-often-always. A score of 
0 represents severe knee impairments and a score of 100 represents no knee 
impairments.
83
 Test-retest reliability ICCs were 0.85, 0.93, 0.75, 0.81 and 0.86 
respectively for each of the measured domains.
83
 A change of ±8 points is needed to 
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demonstrate a clinically meaningful change in patients who undergo ACL 
reconstruction.
82
 For the purposes of this study, the KOOS-P was used to assess pain for 
each of the patients. In addition, the KOOS-ADL and the KOOS-SP were used to assess 
function for each of the patients. 
 12-Item Short-Form Health Survey (SF-12) 
 The SF-12 is a general measure of quality of life that was developed as a 
condensed version of the Medical Outcomes Study 36-Item Short Form (SF-36).
101
 This 
PRO consists of two domains, the physical component summary (PCS) and the mental 
component summary (MCS) which are scored separately.
101
  The SF-12 component 
scores are derived from a scoring algorithm that uses item weights to determine the score 
relative to the representative score of the general population.
101
 The test-retest reliability 
of the PCS-12 was ICC=0.89 and the MSC-12 was ICC=0.76.
101
  For the purposes of this 
study, the SF-12 PCS score will be used as a measure of function. 
 Enzyme-linked immunosorbent assay 
 Serum COMP concentrations were determined using a commercial enzyme-linked 
immunosorbent assay (ELISA, ALPCO, Euro-Diagnostica, Malmo, Sweden, COMP-
200). This ELISA kit utilized a rabbit polyclonal antiserum directed to human COMP and 
the standard curve was determined using native human articular cartilage COMP 
(Wieslab hCOMP quantitative kit, IBL Euro-Diagnostica, Malmo, Sweden). Serum 
COMP values are expressed as ng/mL. The intra-assay coefficient of variation (CV) of 
the controls for each of the assays was <2.5%. The average intra-assay CV of the samples 
for each of the assays was <3.0%.  
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 Bone bruise volumetric measurement 
  The Roemer and Bohndorf technique was employed to determine volumetric 
measurements for each BBL.
81
 This volumetric measurement method was performed 
using the following steps: 1) Using the coronal images: the image with the largest amount 
of signal change was selected, and a straight line from the most peripheral margins of the 
zone of hypertensity were drawn (A); 2) A bisecting orthogonal line (B) was drawn to 
define the second plane; 3) In the sagital plane, a straight line (C) was drawn to connect 
the peripheral images. The volume was then be calculated using the formula: Volume= A 
x B x C.
81
  
 Intrarater reliability for the musculoskeletal radiologist was determined using the 
intraclass correlation coefficient (ICC)3,1. A random number generator was used to 
randomly select 15 subjects from the data set. The radiologist then re-measured the 
volume for each BBL for each of the 15 subjects. If a patient included in the reliability set 
did not have a BBL, they were excluded from analyses. If a patient had only one lesion, 
only that lesion was included in the analysis. Finally, if a patient had 2, 3, or 4 lesions, a 
random number generator was then used to select which BBL would be included in the 
analysis using the following code: 1=LFC, 2=MFC, 3=LTP and 4=MTP.   
 Costa Paz classification system 
 The Costa-Paz classification (CPC) system was employed to determine the 
severity of BBL.
18
 Type I lesions were defined as “a diffuse signal with change of the 
medullary component, often reticular and distant from the subjacent articular surface”; 
Type II defined as: “a localized signal with contiguity to the subjacent articular surface 
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and are usually crescent lesions”; and Type III was defined as: “a disruption or 
depression of the normal contour of the cortical surface” (p.446).18  
 Intrarater reliability for the musculoskeletal radiologist was determined using the 
kappa statistic (κ). A random number generator was used to randomly select 15 subjects 
from the data set. The radiologist then re-assigned the CPC grade for each BBL for each 
of the 15 subjects. If a patient included in the reliability set did not have a BBL, they 
were excluded from the analysis. If a patient had only one BBL, only that lesion was 
included in the analysis. Finally, if a patient had 2, 3, or 4 lesions, a random number 
generator was then used to select which BBL would be included in the analysis using the 
following code: 1=LFC, 2=MFC, 3=LTP and 4=MTP.  
 Classification system for articular cartilage injury 
 The severity of the articular cartilage overlying the bone bruise lesion was 
documented during surgical intervention. The classification normal was given to articular 
cartilage with normal appearance, softening classified articular cartilage that was soft 
when probed but normal on appearance, fissuring classified articular cartilage that had 
visible fissuring or cracks, fibrillation classified articular cartilage that had visible 
fibrillation and defect classified articular cartilage that had visible chondral fractures or 
indentations.
10, 41
 In the event the patient had more than one BBL with visible damage to 
the overlying articular cartilage, the patients were classified according to the more severe 
articular cartilage damage visualized. 
 Data reduction 
 To determine if differences in sCOMP levels, or self-reported pain and function 
exist between patients with BBL and without BBL following AKLI the independent 
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variable was group (BBL present, BBL absent). Subjects included in the BBL group had 
a CPC I, CPC-II, or CPC-III lesion documented on MRI.  Subjects were included in the 
BBL absent group if there were no visible BBL documented on MRI. The dependent 
variable was sCOMP levels (ng/mL). The dependent variables for pain were the scores on 
the IKDC-Pain and the KOOS-P. The dependent variables for function were the scores on 
the IKDC, IKDC-Function, KOOS-ADL, KOOS-SP and SF-Physical. 
 To determine if differences in sCOMP levels and self-reported pain and function 
exist when patients are compared according to differing BBL severities following AKLI, 
the independent variable was BBL severity (as defined by the CPC system). There were 3 
levels of the independent variable. Patients were classified into one of 3 severities (CPC-
I, CPC-II and CPC-III).  If patients had more than one BBL documented on MRI, they 
were classified according to their most severe lesion. The dependent variable was 
sCOMP levels (ng/mL). The dependent variables for pain were the scores on the IKDC-
Pain and the KOOS-P. The dependent variables for function are the scores on the IKDC, 
IKDC current function score (0-10), KOOS-ADL, KOOS-SP and SF-Physical. 
Statistical Analysis 
 All statistical computations were performed using SAS version 9.3 (SAS Institute, 
Cary, NC) or IBM SPSS version 19 (IBM SPSS, Chicago, IL).   
 Demographic descriptive statistics 
 Descriptive statistics (means (SD), counts (percentage)) were calculated for the 
demographic variables measured. Comparisons of demographic variables measured 
between the BBL present and BBL absent groups were performed using an Independent 
samples t-test. In the event the test for equal variance was significant, the unequal 
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variance p-value was reported. Comparisons of demographic variables measured between 
the differing BBL severities (CPC-II and CPC-III) were performed using an Independent 
Samples t-test. There was only one patient in the CPC-I group and this patient’s data 
were removed from the comparisons of demographic variables of interest between the 
different BBL severities. 
 Bone bruise lesion descriptive statistics 
 Descriptive statistics (count (percentage)) were calculated for the side (medial or 
lateral), location (femur or tibia), compartment (LFC, MFC, LTP, MTP) and for CPC 
severity (CPC-I, CPC-II, CPC-III) for the total number of BBL in this cohort. 
Additionally, volumetric measurements (mean (SD)) for each of the locations and 
classifications were calculated for all BBL in this cohort. 
 Reliability 
 Intrarater reliability of the musculoskeletal radiologist’s ability to determine BBL 
volume was estimated using ICC3,1. ICC’s were interpreted as weak if they were less than 
0.40, moderate if between 0.41 and 0.69 and values of more than 0.70 were interpreted as 
strong.
17
 A kappa statistic (κ) was used when determining reliability of the 
musculoskeletal radiologist’s ability to assign CPC grades (CPC-I, CPC-II, CPC-III) 
because these were ordinal data. Intrarater reliability was considered excellent if κ> 0.80, 
substantial if κ 0.79-0.60, moderate if κ 0.59-0.40 and poor if κ<0.39.51 
 Dependent variable descriptive statistics 
 Descriptive statistics (means (SD), counts (percentage)) were calculated for the 
dependent variables collected. Independent samples t-tests were used to determine if 
differences in sCOMP levels, and self-reported pain and function scores (IKDC, IKDC-
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Function, IKDC-Pain, KOOS-P, KOOS-ADL, KOOS-SP and SF-Physical) exist between 
patients with BBL and without BBL following AKLI. In the event the test for equal 
variance was significant, the unequal variance p-value was reported. Independent samples 
t-tests were employed to determine if differences in sCOMP levels or self-reported pain 
and function scores (IKDC, IKDC-Function, IKDC-Pain, KOOS-P, KOOS-ADL, KOOS-
SP and SF-Physical) exist when patients were compared according to BBL severity 
(CPC-II and CPC- III lesions). There was only one patient in the CPC-I group and this 
patient’s data were removed from the comparisons of demographic variables of interest 
between the different BBL severities. Additionally, descriptive statistics (means (SD)) 
and differences in scores on the KOOS-S, KOOS-QOL and SF-Mental were calculated 
and presented. 
 Confounding variable selection 
 Confounding variables were determined based on several factors. These included 
trends identified in the literature, clinical experience, or the results of correlation 
analyses. Furthermore, when determining if differences in BBL severity exist, number of 
lesions and total volume were included as additional confounding variables associated 
with BBL severity. 
 Specific aim #1 
 A one-way ANCOVA was employed to determine if differences in sCOMP levels 
exist between patients with BBL and without BBL using age, BMI and time elapsed from 
injury to data collection as covariates. Alpha was set a priori at 0.05 for all statistical 
tests.  If significant differences were detected, the adjusted means (95% CI) are reported 
for each group. 
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 Specific aim #2 
 A one-way ANCOVA was employed to determine if differences in sCOMP levels 
exist between differing BBL severities (CPC-II and CPC-III) using age, BMI, total 
number of BBL, total BBL volume and time elapsed from injury to data collection as 
covariates. Alpha was set a priori at 0.05 for all statistical tests.  If significant differences 
were detected, the adjusted means (95% CI) are reported for each group. 
 Specific aim #3  
 A one-way ANCOVA was employed to determine if differences in self-reported 
pain (IKDC-Pain, KOOS-P), function (IKDC-function, KOOS-ADL, KOOS-SP, SF-
Physical) and other dependent PRO variables collected (KOOS-S, KOOS-QOL and SF-
Mental) exist when those with and without a BBL were compared while using age, BMI 
and time elapsed from injury to data collection as covariates. Alpha was set a priori at 
0.05 for all statistical tests.  If significant differences were detected, the adjusted means 
(95% CI) are reported for each group. 
 Specific aim #4 
 An ANCOVA was employed to determine if differences in self-reported pain 
(IKDC-Pain, KOOS-P), function (IKDC-Function, KOOS-ADL, KOOS-S and SF-
Physical) and other dependent PRO variables collected (KOOS-S, KOOS-QOL and SF-
Mental) when compared according to BBL severity using age, BMI, total number BBL, 
total BBL volume and time elapsed from injury to data collection as covariates. Alpha 
was set a priori at 0.05 for all statistical tests.  If significant differences were detected, 
the adjusted means (95% CI) are reported for each group. 
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 Exploratory regression analysis 
 An exploratory logistic regression analysis was performed to determine a 
predicative model for BBL presence and BBL severity using the significant regressors 
from the one-way ANCOVAs.  The area under the curve (AUC) from the receiver 
operator characteristic curve was used to determine how well the significant regressors 
predict the outcome of interest (BBL presence or BBL CPC-III). First, univariate logistic 
regression was performed to determine the AUC for each regressor. Finally, a bivariate 
logistic regression was performed to determine the AUC for all significant regressors.  
Results 
 A total of 59 patients consented to participate in this research study.  One patient 
did not complete any of the PRO forms; therefore data for 58 patients were available for 
these dependent variables. Additionally, serum data were available for 51 patients. 
Reasons for missing serum data were due to the inability to collect serum from the patient 
or the patient refused collection.  Finally, 47 of the 52 patients with BBL had data 
available regarding damage to the overlying articular cartilage. Missing articular cartilage 
scores were either due to the patient not undergoing surgery, or the articular cartilage 
score was unavailable following surgery.  
Demographic Descriptive Statistics 
 Descriptive statistics for the demographic characteristics for each of the BBL 
group can be found in Table 4.1. There were no significant differences in demographic 
characteristics between the BBL absent and BBL present groups (p>0.05).  Descriptive 
statistics for the demographic characteristics for each of the severity groups (CPC-I, 
CPC-II and CPC-III) can be found in Table 4.2. There were no significant differences in 
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demographic characteristics between the severity groups. However, it is of interest to 
note that there was a significant difference in time elapsed from injury to data collection 
(p=0.04), with patients in the CPC-III group having more time elapsed  between time of 
injury to data collection compared to the patients in the CPC-II group. 
Bone Bruise Lesion Descriptive Statistics 
 A total of 52 patients had BBL documented on MRI. Of these patients, 7(13.5%) 
had 1 BBL, 15 (28.8%) had 2 BBL, 16 (30.8%) had 3 BBL and 14 (26.9%) had 4 BBL 
documented on MRI.  
 A total of 143 BBL were documented on MRI for the entire cohort. The average 
volume for all 143 BBL was 4.4 (8.1) cm
3
. A majority of the lesions were located on the 
lateral side and the lateral sided lesions had larger volume when compared to the medial 
side (Table 4.3). The LFC lesions had the largest volume, followed by the lesions on the 
LTP. A majority of the lesions in this cohort were CPC-II (77.8%), while the least 
amount of BBL in this cohort were CPC-I (5.6%). Finally, CPC-III lesions appear to have 
the largest volume when compared to the CPC-I and CPC-II lesions. Counts 
(percentages) and volume means (SD) for each of the locations, sides, compartments and 
CPC severity for all of the BBL can be found in Table 4.3. 
 There was articular cartilage damage at time of arthroscopy data available for 47 
patients. Descriptive statistics for the visible articular cartilage for patients with BBL and 
for differing BBL severity groups can be found in Table 4.4 and 4.5 respectively. The 
results of our study indicate that a majority of the articular cartilage overlying BBL is 
normal in appearance. However our results indicate that 11 BBL had visual articular 
cartilage damage overlying the LFC (6 softening, 4 fissuring, 1 defect); 9 BBL had 
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visualized articular cartilage damage in the LTP (7 softening and 2 fissuring); 4 BBL had 
visualized damage in the articular cartilage overlying the MTP (3 softening and 1 
fissuring) and 3 BBL had visualized damage to the articular cartilage in the MFC (2 
softening and 1 fissuring). Type II and Type III lesions had more visible changes to the 
overlying articular cartilage as: 10 Type II lesions were soft to probe, 6 Type II lesions 
had visible fissuring and 1 Type II lesion had visible defect. In contrast, 4 Type III 
lesions were soft to probe and 2 Type III lesions had visible fissuring while only 4 Type I 
lesions had softening when probed. 
Reliability 
   The results of the ICC3,1 indicated the musculoskeletal radiologist had excellent 
reliability when measuring BBL volume, ICC=0.99.  Furthermore, the musculoskeletal 
radiologist had substantial agreement when assigning CPC grades (κ=0.76).  
Dependent Variable Descriptive Statistics 
 Means (SD) and counts (percentage) for the dependent variables measured for 
each of the BBL group can be found in Table 4.4. The results of the Independent samples 
t-test revealed there were significant differences on two PROs between the groups, with 
the BBL absent group having significantly higher scores on the KOOS-S (p=0.01) and 
KOOS-QOL (p=0.04) when compared to the BBL present group. In addition, means (SD) 
and counts (percentage) for the dependent variables measured for each of the severity 
groups (CPC-I, CPC-II and CPC-III) can be found in Table 4.5. The results of the 
Independent samples t-test employed to determine differences between the severity 
groups (CPC-II and CPC-III) revealed no significant differences. However, there was a 
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trend noted for total BBL volume, with patients in the CPC-III BBL group have larger 
volume when compared to the CPC-II (p=0.08).  
Specific Aim #1 
 For specific aim #1, we aimed to determine if differences in sCOMP levels exist 
between patients with BBL and without BBL. While controlling for confounding 
variables (age, BMI, time elapsed from injury to serum collection) the results of the 
ANCOVA revealed there are no significant differences in sCOMP levels between 
patients with and without BBL (Omnibus F-test, p=0.08).  
Specific Aim #2 
 For specific aim #2, we aimed to determine if differences in sCOMP levels exist 
when patients were compared according to differing BBL severities (CPC-II and CPC-
III). While controlling for potential confounding variables (age, BMI, time elapsed from 
injury to serum collection, total BBL volume and total number of BBL) the results of the 
ANCOVA revealed there are no significant differences in sCOMP levels between BBL 
severities (Omnibus F-test, p=0.35). 
Specific Aim #3 
 For specific aim #3, we aimed to determine if differences in self-reported pain and 
function exist between patients with BBL and without BBL. While controlling for 
confounding variables (age, BMI, time elapsed from injury to data collection) the results 
indicated patients with BBL reported more knee related symptoms when performing 
ADLs (60.9, 95% CI: 56.1-65.8), as measured by the KOOS-ADL, when compared to 
patients without BBL (75.0, 95% CI: 61.9-88.2, p=0.05).  There were no other significant 
differences between the other variables. 
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Specific Aim #4 
 For specific aim #4, we aimed to determine if differences in self-reported pain and 
function exist when patients were compared according to differing BBL severities (CPC-
II and CPC-III). While controlling for potential confounding variables (age, BMI, time 
elapsed from injury to data collection, total BBL volume and total number of BBL) for 
each of the severity groups, the results indicated patients with CPC-III BBL reported 
more knee related symptoms when performing sport related activities (9.5, 95% CI: 1.7-
17.3), as measured by the KOOS-SP, when compared to patients with CPC-II BBL (21.2, 
95% CI: 14.7-27.8, p=0.03).  
 For the remaining dependent variables that were collected, significant differences 
between the BBL presence and BBL absent groups were revealed for the KOOS-QOL. 
Based on the results of the one-way ANCOVA, when controlling for confounding 
variables, patients without BBL reported higher levels on the KOOS-QOL (46.1, 95% CI: 
33.9-58.4) when compared to patients with BBL (30.1, 95% CI: 25.6-34.6, p=0.02). 
Additionally, when patients are compared according to differing BBL severity, patients 
with less severe lesions (CPC-II) report higher levels on the KOOS-QOL (35.2, 95% CI: 
29.4-41.1) when compared to patients with CPC-III lesions (24.2, 95% CI: 17.2-31.2, 
p=0.03).  
Exploratory Regression Analysis 
 BBL presence 
 A univariate logistic regression was employed to predict BBL presence and it was 
found that the AUC for the KOOS-QOL was 0.73 and the AUC for the KOOS-ADL was 
0.70. Using a bivariate logistic regression for both regressors, the AUC was 0.76. 
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Therefore, based on these results it appears the combination of these two PROs will 
predict BBL presence roughly 76% of the time. However it must be cautioned that this is 
a preliminary analysis and more subjects are needed to properly interpret these results. 
 BBL severity 
 The results of the univariate logistic regression predicting the most severe BBL 
(CPC-III) revealed the AUC for the KOOS-SP was 0.59 and the AUC for the KOOS-
QOL was 0.58. Using a bivariate logistic regression for both regressors the AUC was 
0.60. Therefore, based on these results it appears a combination of these two PROs will 
predict the most severe BBL (CPC-III) approximately 60% of the time. However it must 
be cautioned that this is a preliminary analysis and more subjects are needed to properly 
interpret these results. 
Discussion 
 The study was the first to document if differences in sCOMP levels, and self-
reported pain and function scores exist for patients with and without BBL and for patients 
with differing BBL severities following AKLI. The results of this study revealed there are 
no differences in sCOMP levels between patients with and without BBL or between 
differing BBL severities. In addition, we were able to determine that patients with BBL 
report more functional deficits, as measured by the KOOS-ADL than patients without 
BBL pre-operatively. Furthermore, patients with more severe BBL (CPC-III) reported 
more functional deficits, as measured by the KOOS-SP, than patients with less severe 
BBL (CPC-II). Finally, it was determined that patients with BBL and with more severe 
BBL report lower levels on the KOOS-QOL compared to patients without BBL and with 
less severe lesions (CPC-II).  
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 Numerous studies have proposed the modification of protected weight bearing to 
current rehabilitation protocols for patients with severe BBL prior to and following 
ligament reconstruction.
16, 24, 50, 71, 84, 91, 103
 However, when reviewing the BBL literature 
there is inconsistent use of a severity measurement for these lesions. Few severity 
classification systems for BBL exist in the literature.
18, 59
 While the definitions of the 
CPC-I and CPC-II lesions are quite similar to Type I and Type II lesions in the 
classification of proposed by Lynch et al.
59
 for the purposes of this study, we chose the 
CPC system.
18
  The advantage of the CPC systems is  CPC-III grade lesions involve 
damage to the cortical surface and it was our hypothesis that the involvement of the 
cortical surface would represent more damage to the overlying articular cartilage,
18
 
compared to the Type III classification described by Lynch  that specifically states there 
is no cortical disruption.
59
  
 Few studies have used these severity classifications for BBL.
18, 59, 84
 The results of 
the Costa-Paz study
18
 revealed 13 (44.8%) CPC-I lesions, 11 (37.9%) CPC-II lesions and 
5 (17.2%) CPC-III lesions. Additionally, the results of the Lynch et al. study revealed 99 
(69.7%) Type I lesions, 19 (13.4%) Type II lesions and 24 (16.9%) Type III lesions.
59
 
Additionally, Rosen et al.
84
 used a modified Lynch et al.
59
 classification where Type I 
was located in the meduallary bone without cortical disruption and Type II lesions had an 
interruption of the cortex. This report indicated 76 of the 84 BBL were Type I and 8 were 
Type II.
84
 While our study had substantially more BBL compared to the Costa-Paz 
study,
18
 and comparable numbers to that of Lynch et al.,
59
 and Rosen et al.,
84
 our results 
indicated a majority of the lesions were CPC-II (112, 78%). In fact, the fewest BBL 
documented in our patients were CPC-I (8, 5.5%), which was the majority of the lesions 
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documented for each of the aforementioned investigations.
18, 59, 84
 However, we must use 
caution when comparing our results to the Lynch et al.
59
 study as their study was 
retrospective and patients were included if they had osteoarthritis.
59
 Additionally, our 
results support the findings of Costa-Paz
18
 in that the most of the CPC-I lesions are 
located in the LTP (3/8, 37.5%) but we also found an equal number in the MFC (3/8, 
37.5%) and a majority of the CPC-III lesions are located in the LFC (18/23, 78.3%).
18
 
However, our results indicate that  more of the CPC-II lesions occur in the LTP (41/112, 
36.7%) as opposed to the LFC proposed by Costa-Paz.
18
 Regardless of the classification 
system used, it does appear that there are trends for more severe lesions to be located in 
the lateral compartment. While lateral compartment BBL are commonly associated with 
AKLI, severity classification systems should be used to further understand the outcome 
of these lesions.
7, 18
 
 While this study was cross-sectional in nature, previous researchers have 
reassessed patients using  repeat MRI an average of 34 months after injury.
18
 The results 
of the repeat MRI revealed that 1 (9%) of the CPC-II lesions and all 5 (100%) of the 
CPC-III lesions remained visible and the 5 CPC-III BBL patients had associated articular 
damage on MRI.
18
 Of our 52 patients with documented BBL, 30 had at least 1 CPC-II 
lesion and 21 had at least 1 CPC-III lesion documented on MRI. If we apply the results of 
Costa-Paz to our patients, it is estimated roughly 40-45% of the patients included in this 
study will have articular cartilage changes visible on MRI approximately 2-3 years after 
injury.
18
 The mean age of our patients with BBL is approximately 21 years; if they are 
likely to have articular changes within a 2-4 year period, it would indicate that 40% of 
our patients will have articular changes prior to 30 years of age. Regardless of whether 
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the ACL is reconstructed or not, it is a concern of many physician and scientists that 
articular cartilage changes occur very rapidly and these patients will develop visible 
PTOA 10-20 years after injury.
54, 57, 91, 99
 While alterations in current treatment 
rehabilitation protocols for patients with severe BBL is not supported by evidence, it 
remains quite clear that severe BBL should be acknowledged and further research 
regarding their relationship with articular cartilage changes are warranted. 
 We also measured BBL volume as an additional measure to support BBL 
severity. The volumetric technique selected for the purposes of this study was that 
described by Roemer and Bohndorf.
81
 This technique was chosen as it was believed this 
technique could be accurately applied to all MRIs, given that our study did not exclude 
patients based on where the MRI was obtained. The average BBL volume for the Roemer 
and Bohndorf cohort was 14.75cm
3
. The average volumetric measurement of the BBL in 
this study was 4.4cm
3
, which appears to be quite different than that of Roemer and 
Bohndorf.
81
 These differences may exist due to differing imaging techniques as the 
Roemer and Bohndorf 
81
 study utilized STIR images, and all of the MRIs in our study did 
not have STIR images. However, of even more interest is the follow-up MRIs of 49 
patients from the original study.
81
 A total of 49 patients were re-evaluated approximately 
2 years after injury and 6 BBL remained visible at follow-up, with an average volume of 
2.26cm
3
.
81
 The authors did not report the index volumetric measurements of the BBL that 
were visible on the follow-up MRI, therefore we cannot conclude whether the largest 
lesions were those that remained visible at follow-up. However, the authors concluded 
the remaining BBL had visible articular cartilage damage on MRI and this may be the 
beginning signs of PTOA changes.
81
 While the long term outcome of BBL is poorly 
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understood, it appears that the use of a severity classification system or a volumetric 
measurement technique is important to identify if these lesions are related to the 
development of early degenerative changes in longitudinal studies.   
 The identification of articular cartilage injury overlying BBL at the time of 
arthroscopy has been inconsistent in the literature. For the purposes of this study, we 
asked the orthopaedic surgeon to visualize the articular cartilage overlying the BBL and 
report either: normal, softening, fissuring, fibrillation, or defect. For the patients for 
which we had  these data (Table 4.4), the results indicated that the most severe damage to 
the articular cartilage overlying BBL was softening (17%), followed by fissuring (11%) 
and chondral defect (2.2%,). Furthermore, we were able to compare the visualization of 
the articular cartilage overlying the BBL between the differing CPC severities. The 
results of a smaller study (n=10) revealed damage to the overlying articular cartilage for 
all patients with BBL.
41
 The damage in this cohort ranged from softening to chondral 
defect, with the most common damage being softening of the area.
41
 A second report that 
investigated articular cartilage changes in the LFC and LTP revealed 14.7% of the LFC 
BBL had visual articular cartilage damage and 34.4% of the LTP BBL had visual 
articular cartilage damage.
76
 Data concerning the actual damage sustained to the area 
were only presented for the LTP and  the results indicated that 18  were classified as 
ICRS grade I (softening) and 11 were ICRS grade II (fibrillation).
76
 It appears that 
visualization of the damage to the articular cartilage overlying the BBL may not represent 
the extent of the damage to these areas. In order to truly quantify the amount of damage 
that has occurred to these overlying areas, a more specific measurement of articular 
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cartilage damage, such as biopsy for further immunohistochemical staining may be 
warranted. 
 Recent evidence has shown sCOMP levels were significantly increased in patients 
with AKLI compared to healthy controls.
47
 Given that 80% of MRIs diagnosing AKLI 
have documented BBL, we hypothesized patients with BBL would have damage to the 
articular cartilage that would be measurable using sCOMP. Furthermore, we 
hypothesized patients with more severe BBL would have higher levels of sCOMP, 
indicating more articular cartilage damage compared to the less severe lesions. However, 
our results indicated there are no differences in sCOMP levels between patients with 
BBL (1362.5±310.0) and without BBL (1509.1±384.6), and between patients with CPC-
II lesions (1407.9±322.5) and patients with CPC-III lesions (1315.2±296.5). Because the 
ELISA that was utilized for this study was not used in previous research, it is hard to 
make direct comparisons to the literature that has measured sCOMP in patients with 
AKLI.
13, 19, 47, 58
  However, we can speculate why these differences might not have been 
detected amongst these groups. First, the patients in our study could have suffered an 
AKLI up to four weeks prior to inclusion in our study. Numerous researchers have 
reported that serum or synovial levels of COMP are highest immediately after injury.
19, 58
 
Potentially the time elapsed from injury to serum collection was too long to detect 
measurable differences for the patients in our study.  However, one must take into 
consideration the utility of this marker, if there is only a short window of opportunity to 
measure the levels at their highest, this marker may not be clinically useful given that the 
clinical population may not be accessible relatively soon after injury. Second, we 
collected sCOMP as opposed to synovial fluid levels of COMP, and potentially serum 
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levels of COMP are not specific enough to detect these differences. While one study has 
supported differences in sCOMP levels between patients with AKLI and healthy 
controls,
47
 another study did not find differences.
58
 It could be speculated that differences 
in the Kuhne et al.
47
 study were detected as the patients included had more severe damage 
to the articular cartilage following AKLI, however, these data were not presented. 
However, studies have reported differences in the synovial levels of this biomarker when 
patients are compared to healthy controls.
19, 58
 Therefore, synovial levels of this 
biomarker may be a better indicator of the damage to articular cartilage as the release of 
COMP in the synovial fluid may be specific enough to represent the damage associated 
with BBL. However, not all patients that report to the physician’s office will have an 
effusion to warrant removal of the fluid for assessment. Additionally, while these studies 
report differences in synovial levels for patients with AKLI compared to healthy controls, 
synovial levels are the highest when sampled closer to the time of injury.
19, 58
 While 
justification of collecting synovial samples at each clinic visit may be difficult, one could 
justify taking synovial samples at the time of surgery. However, given that each of the 
studies that have collected synovial fluid COMP levels also documented these levels are 
highest closer to the time of injury,
19, 58
 a time of surgery sample may not truly represent 
the initial level of damage sustained to the articular cartilage as surgery is not often 
immediate following AKLI. 
 Multiple studies have investigated differences in pain, function and symptoms for 
patients with AKLI with and without BBL.
23, 38, 42, 97
 The results of these studies were 
inconsistent, likely because multiple methods of measuring pain, function and symptoms 
were utilized or possibly because BBL severity may affect these outcomes. When 
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controlling for confounding variables (age, BMI and time from injury to data collection) 
we found patients with BBL to have lower scores on the KOOS-ADL when compared to 
patients without BBL. These results indicate patients with BBL have a more difficult time 
performing functional activities related to ADLs due to their knee pathology, when 
compared to patients without BBL. A recent investigation also found differences in 
function between patients with and without BBL  using the Noyes function scale, with 
BBL patients having significantly more self-reported functional deficits compared to 
patients without BBL.
97
 Barring any immediate need for surgical reconstruction, most 
surgeons will wait to perform anterior cruciate ligament reconstruction (ACLR) until the 
patient has regained full ROM, achieved normal gait and had no effusion.
42
 A recent 
investigation reported patients with BBL had more effusion that lasted longer than 
patients without BBL, used crutches to ambulate longer than patients without BBL and 
took longer to regain full ROM compared to patients without BBL.
42
 The clinical 
characteristics that were measured could cause a patient to have difficulty completing 
their ADLs, especially those activities measured in the KOOS-ADL.
83
  It must be noted 
that we did not measure these characteristics, such as presence of effusion, size of 
effusion, or ROM deficits in our cohort.  Additionally, when controlling for age, BMI and 
time elapsed from injury to data collection, we reported differences in knee related 
quality of life, with patients with BBL reporting lower levels on the KOOS-QOL 
compared to patients without BBL. These results indicate patients with BBL are more 
aware of their knee problems, have made more modifications to their activities because of 
their knee, report a lack of confidence in their knee and report more difficulty with their 
knee compared to the patients without BBL.
83
 While all patients with AKLI have some 
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level impairment, it appears the BBL group may have more impairment, resulting in 
participation restrictions and activity limitations, as measured via the KOOS-ADL, 
resulting in a lower health related quality of life. 
 When controlling for confounding variables, we did not find differences in pain, 
as measured by the KOOS-P for patients with and without BBL, which supports recent 
findings where no differences in KOOS-P were found between patients with and without 
BBL.
23
 Additionally, we found no differences in the IKDC-Pain score, which was 
derived from the IKDC score to represent a 0-10 likert scale used in previous research.  
These results support a recent investigation that reported only a 0.23 difference between 
patients with BBL and without BBL.
6
 One study measured differences in a likert pain 
scale, with patients with BBL reporting a pain value of 6.1 compared to a 2.9 reported by 
patients without BBL.
42
  In addition it was  reported that the patients with BBL had a 
larger effusion and decreased ROM.
42
 While we did not measure these clinical variables, 
pain differences detected by Johnson et al.
42
 may have been related to increases effusion 
and the resultant decreased ROM.  
 We hypothesized the differences in pain, function and symptoms for patients with 
and without BBL were conflicting because differences may exist based on BBL severity 
rather than presence. As a result, it is possible that  the patients included in studies which 
reported differences in pain and function
42, 97
 contained a cohort of patients with more 
severe BBL, while the studies that did not detect differences contained cohorts with less 
severe BBL.
6, 23
 Therefore, we also examined whether or not differences in self-reported 
pain and function exist when patients with BBL were compared according to differing 
BBL severities. Our results indicated there are differences in function related to sports 
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and recreation when controlled for confounding variables, as measured by the KOOS-SP, 
as patients with more severe BBL (CPC-III) reported more difficulty in performing sports 
related activities compared to less severe BBL (CPC-II). Furthermore, when controlling 
for confounding variables, our results indicated patients with more severe BBL reported 
lower scores on the KOOS-QOL compared to patients with less severe lesions and these 
data in conjunction with a decrease in KOOS-SP also seem appropriate as these patients 
are unable to participate in meaningful activities and this is reflected in their lower 
KOOS-QOL scales. 
 This study was exploratory in nature with the primary aim of determining if a 
cartilage degradation marker, specifically sCOMP, could detect acute articular cartilage 
damage associated with BBL and whether or not there would be differences for patients 
with more severe BBL. We did not detect differences between either of the groups and 
this could be because sCOMP is not specific enough for the damage that is sustained. 
Future research studies should explore other markers of articular cartilage degradation 
that have been utilized in patients with AKLI, such as synovial fluid COMP,
19, 58
 
CTxII,
13, 53
 MMP-3
5, 13
 or aggrecan markers.
13, 58
 Future research studies should 
incorporate measures of BBL severity when trying to address the longitudinal outcomes 
of these lesions. Utilizing a severity classification system or volumetric technique may 
further elucidate the likelihood of patients developing PTOA following AKLI. Adding a 
volumetric measurement to the severity classification systems may allow for better 
quantification of the rate of resolution of BBL for future longitudinal research studies. 
Finally, in order to better measure the amount of damage occurring to the articular 
cartilage overlying these lesions, future research studies should incorporate a direct 
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measurement of articular cartilage damage to identify whether or not there are differences 
in the amount of damage for each of the BBL severity classifications.  
Limitations 
 This study is not without limitations. First, a single radiologist measured the 
volume of the BBL and assigned the CPC severity for each of the lesions. While we 
demonstrated sufficient intrarater reliability for each of the measurements, we were 
unable to compare these results to other raters. Additionally, multiple surgeons viewed 
and scored the articular cartilage overlying the BBL during arthroscopy. We were unable 
to determine the intrarater or interrater reliability of these surgeons when assigning these 
scores to the articular cartilage. While BBL were most commonly identified on MRI 
diagnosing for ACL injury, we included patients with injuries to PCL and MCL and 
patients with multiple AKLI. Finally, multiple MRI machines were used for this research 
study. Patients were not excluded from participating in this research study if they 
obtained an MRI outside of the University of Kentucky radiology department.  
Conclusions 
 The results indicate there are no differences in sCOMP levels when patients are 
compared according to BBL presence/absence or by differing severities. However, 
caution must be utilized during interpretation of these results as the group of patients 
without a BBL and with the least severe BBL (CPC-I) were very small. Additionally, we 
were able to demonstrate patients with BBL reported a decrease in function related to 
ADLs compared to patients without BBL and patients with more severe BBL reported a 
decrease in function related to sports participation compared to patients with less severe 
BBL. The utilization of a BBL severity classification may further elucidate those patients 
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that have functional deficits prior to surgical reconstruction. Future research studies with 
larger cohorts are needed to confirm or dispute the findings within this study. 
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Table 4.1: Summary of the Demographic Characteristics (Mean (Standard Deviation 
(SD) or Count (Percentage)) Collected for the Entire Sample and for the Groups (Bone 
Bruise Lesion (BBL) present, BBL absent). 
 All subjects 
(N=59) 
BBL Present 
(N=52) 
BBL Absent  
(N=7) 
Age 
     N 
     Mean (SD) 
 
59              
21.4 (8.7) 
 
52              
21.0 (8.8) 
 
7                
23.9 (7.8) 
Height (cm) 
     N 
     Mean (SD) 
 
58              
174.6 (9.6) 
 
51              
174.0 (9.6) 
 
7               
178.7 (9.1) 
Weight (kgs) 
     N 
     Mean (SD) 
 
58              
80.0 (20.3) 
 
51              
77.2 (21.1) 
 
7                
83.6 (12.8) 
BMI 
     N 
     Mean (SD) 
 
58              
25.4 (5.2) 
 
51              
25.3 (5.4) 
 
7                
 26.3 (3.1) 
Injury to MRI (days) 
      N 
      Mean (SD) 
 
59              
4.7 (3.9) 
 
52              
4.7 (3.8) 
 
7                
 4.7 (4.6) 
MRI to Data (days) 
     N 
     Mean (SD) 
 
59              
6.2 (6.0) 
 
52              
6.0 (5.3) 
 
7                
7.6 (10.4) 
Injury to Data (days) 
     N 
     Mean (SD) 
 
59              
10.9 (7.8) 
 
52              
10.7 (7.1) 
 
7                
12.3 (12.6) 
Sport  
     N 
     Soccer 
     Football 
     Basketball 
     Other 
 
59              
14 (23.7)        
11 (18.6)        
22 (37.3)        
12 (20.3) 
 
52              
12 (23.1)         
10 (19.2)         
21 (40.4)         
9 (17.3) 
 
7               
2 (28.6)           
1 (14.3)           
1 (14.3)           
3 (42.9) 
Race 
     N 
     Caucasian 
     African American 
     Other 
 
59              
50 (84.8)        
4 (6.8)          
5 (8.5) 
 
52             
43 (82.7)         
4 (7.7)           
5 (9.6) 
 
7                
7 (100.0)          
0 (0.0)            
0 (0.0) 
Injured Side 
     N 
     Left 
     Right 
 
59              
34 (57.6)        
25 (42.4) 
 
52              
29 (55.8)         
23 (44.2) 
 
7                
5 (71.4)           
2 (28.6) 
Gender 
     N 
     Male 
     Female 
 
59              
32 (54.5)        
27 (45.6) 
 
52              
27 (51.9)         
25 (48.1) 
 
7                
5 (71.4)           
2 (28.6) 
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Table 4.2: Summary of the Demographic Characteristics (Mean (Standard Deviation 
(SD), or Count (Percentage)) Collected for the Entire Sample with BBL and for Each of 
the Severity Groups (Costa-Paz Classification
18
 (CPC)-I, CPC-II, CPC-III). 
 All subjects 
(N=52) 
CPC-I 
(N=1) 
CPC-II 
(N= 30) 
CPC-III 
(N=21) 
Age 
     N 
     Mean (SD) 
 
52                     
21.0 (8.8) 
 
1                     
15 
 
30                      
21.5 (9.0) 
 
21                      
20.7 (8.9) 
Height (cm) 
     N 
     Mean (SD) 
 
51                      
174.0 (9.6) 
 
1                   
150.0 
 
30                  
173.7 (8.9) 
 
21                   
175.5 (9.3) 
Weight (kgs) 
     N 
     Mean (SD) 
 
51                     
77.2 (21.1) 
 
1                     
63.6 
 
30                     
75.6 (19.0) 
 
21                     
81.5 (23.9) 
BMI 
     N 
     Mean (SD) 
 
51                      
25.3 (5.4) 
 
1                     
28 
 
30                     
24.4 (4.4) 
 
21                     
26.4 (6.6) 
Injury to MRI 
      N 
      Mean (SD) 
 
52                     
4.7 (3.8) 
 
1                       
2 
 
30                      
4.1 (3.0) 
 
21                      
5.5 (4.8) 
MRI to Data 
     N 
     Mean (SD) 
 
52                      
6.0 (5.3) 
 
1                      
11 
 
30                      
4.9 (3.7) 
 
21                      
7.4 (6.8) 
Injury to Data 
     N 
     Mean (SD) 
 
52                      
10.7 (7.1) 
 
1                      
13 
 
30                     
9.0 (5.3) 
 
21                      
13.1 (8.8) 
Sport  
     N 
     Soccer 
     Football 
     Basketball 
     Other 
 
52                      
12 (23.1)           
10 (19.2)           
21 (40.4)              
9 (17.3) 
 
1                       
1 (100.0)           
0 (0.0)              
0 (0.0)              
0 (0.0) 
 
30                    
6 (20.7)           
7 (23.3)           
13 (43.3)           
4 (13.3) 
 
21                      
5 (23.8)             
3 (14.3)             
8 (38.1)             
5 (23.8) 
Race 
     N 
     Caucasian 
     African Am. 
     Other 
 
52                      
43 (82.7)             
4 (7.7)                 
5 (9.6) 
 
1                        
1 (100.0)           
0 (0.0)              
0 (0.0) 
 
30                      
24 (80.0)           
3 (10.0)           
3 (10.0) 
 
21                      
18 (85.7)            
1 (4.8)               
2 (9.5) 
Injured Side 
     N 
     Left 
     Right 
 
52                      
29 (55.8)           
23 (44.2) 
 
1                        
0 (0.0)              
1 (100.0) 
 
30                      
20 (66.7)           
10 (33.3) 
 
21                      
9 (42.9)            
13 (61.9) 
Gender 
     N 
     Male 
     Female 
 
52                      
27 (52.0)           
25 (48.1) 
 
1                       
0 (0.0)              
1 (100.0) 
 
30                       
16 (53.3)            
14 (46.7) 
 
21                      
11 (52.4)           
10 (47.6) 
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Table 4.3: Summary of the Number of Bone Bruise Lesions (BBL) and Volumetric 
Measurement for all Lesions, Side (Medial (M) or Lateral (L)), Location (Femoral 
Condyle (FC) or Tibial Plateau (TP), Compartment (LFC, MFC, LTP, MTP) and Costa-
Paz Classification
18
 (CPC) Severities (CPC-I, CPC-II and CPC-III).  
 Number of BBL Mean (SD) cm
3
 
Total 143 4.4 (8.1) 
Side 
     L 
     M 
 
91(63.2%)                       
52 (36.8%) 
 
6.0 (9.7)                       
1.8 (1.9) 
Location 
     FC 
     TP 
 
62 (43.1%)                     
81 (56.9%) 
 
5.6 (10.7)                  
3.5 (5.2) 
Compartment 
     LFC 
     MFC  
     LTP 
     MTP                                                                        
 
43 (29.9%)                     
19 (13.2%) 
48 (33.3%)                     
33 (22.9%)
 
7.5 (12.3)                     
1.3 (1.6) 
4.6 (6.4)                     
2.0 (2.1) 
Severity 
     CPC-I 
     CPC-II 
     CPC-III 
 
8 (5.6%)                      
112 (77.8%) 
23 (16.0%)                    
 
4.4 (5.5)                    
3.0 (5.5) 
11.3 (14.1)                     
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Table 4.4: Summary of the Dependent Variables (Mean (Standard Deviation)* Collected 
for the Entire Sample and for Each Group (Bone Bruise Lesion (BBL) Present, BBL 
Absent). 
 All Subjects 
(N=59) 
BBL Present 
(N=52) 
BBL Absent 
(N=7) 
sCOMP (ng/mL) 
     N 
     Mean (SD) 
 
51              
1379.7 (318.8) 
 
45               
1362.5 (310.0) 
 
6                 
1509.1 (384.6) 
IKDC 
     N 
     Mean (SD) 
 
58               
35.5 (13.6) 
 
51               
35.0 (14.4) 
 
7                 
38.9 (10.4) 
IKDC-Pain 
     N 
     Mean (SD) 
 
58               
5.8 (2.6) 
 
51               
5.8 (2.7) 
 
7                 
6.1 (2.1) 
IKDC-Function 
     N 
     Mean (SD) 
 
58              
4.3 (1.9) 
 
51               
4.3 (2.0) 
 
7                 
4.4 (1.1) 
KOOS-P 
     N 
     Mean (SD) 
 
58               
57.9 (18.3) 
 
51               
57.0 (18.9) 
 
7                 
64.7 (11.8) 
KOOS-S 
     N 
     Mean (SD) 
 
58               
57.7 (10.5) 
 
51               
56.6 (10.0) 
 
7                 
66.9 (10.1) 
KOOS-ADL 
     N 
     Mean (SD) 
 
58               
62.6 (20.7) 
 
51               
60.9 (20.9) 
 
7                 
75 (14.2) 
KOOS-SP 
     N 
     Mean (SD) 
 
58               
17.5 (22.3) 
 
51               
16.0 (20.3) 
 
7                 
28.6 (33.9) 
KOOS-QOL 
     N 
     Mean (SD) 
 
58               
32.1 (18.1) 
 
51               
30.3 (17.7) 
 
7                 
45.3 (16.4) 
SF-Mental 
     N 
     Mean (SD) 
 
58               
50.3 (9.8) 
 
51              
49.6 (10.2) 
 
7                 
53.2 (5.6) 
SF-Physical 
     N 
     Mean (SD) 
 
58               
36.5 (8.7) 
 
51               
36.3 (8.5) 
 
7                 
38.6 (10.5) 
BB Total Volume (cm3)† 
     N 
     Mean (SD) 
 
59               
10.8 (16.2) 
 
52               
12.2 (3.8) 
 
7                 
0 (0.0) 
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Table 4.4 (continued) 
 
Articular Cartilage 
Damage 
     N 
     Normal 
     Softening 
     Fissuring 
     Fibrillation 
     Defect 
 
 
47                      
33 (70.2)           
8 (17.0)           
5 (10.6)                
0 (0.0)            
1 (2.1) 
 
 
47                      
33 (70.2)           
 8 (17.0)             
5 (10.6)                 
0 (0.0)              
1 (2.1) 
 
 
4                          
 0 (0.0)                
0 (0.0)                  
0 (0.0)                     
0 (0.0)                  
0 (0.0) 
* sCOMP: serum cartilage oligomeric matrix protein, IKDC: International Knee 
Documentation Committee Subjective Knee Form, IKDC- Pain: International Knee 
Documentation Committee Subjective Knee Form Pain Scale, IKDC-Function: 
International Knee Documentation Committee Subjective Knee Form Function Scale, 
KOOS-P: Knee Injury and Osteoarthritis Outcome Score-Pain, KOOS-S: Knee Injury 
and Osteoarthritis Outcome Score- Symptoms, KOOS-ADL: Knee Injury and 
Osteoarthritis Outcome Score- Activities of Daily Living, KOOS-SP: Knee Injury and 
Osteoarthritis Outcome Score- Sports and Recreation, KOOS-QOL: Knee Injury and 
Osteoarthritis Outcome Score- Quality of Life, SF-Mental: 12-Item Short Form Health 
Survey Mental Component Score, SF-Physical: 12-Item Short Form Health Survey 
Physical Component Score. 
† Total volume is the sum of the volume for each of the lesions present on MRI for the 
patient. 
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Table 4.5: Summary of the Dependent Variables* (Mean (Standard Deviation (SD)), or 
Count (Percentage)) Collected for the Entire Sample with Bone Bruise Lesions (BBL) 
and for each Severity (Costa-Paz Classification
18
 (CPC)-I, CPC-II, CPC-III). 
 All subjects 
(N=52) 
CPC-I  
(N=1) 
CPC-II 
(N= 30) 
CPC-III 
(N=21) 
sCOMP (ng/mL) 
     N 
     Mean (SD) 
 
45                             
1362.5 (310.0) 
 
1                            
1125 
 
25                    
1407.9 (322.5) 
 
19                      
1315.2 (296.5) 
IKDC 
     N 
     Mean (SD) 
 
51                              
35.0 (14.4) 
 
1                           
29.9 
 
29                 
34.9 (11.3) 
 
21                   
35.5 (18.3) 
IKDC- Pain 
     N 
     Mean (SD) 
 
51                              
5.8 (2.7) 
 
1                           
10 
 
29                 
5.2 (2.7) 
 
21                   
6.4 (2.4) 
IKDC- Function 
     N 
     Mean (SD) 
 
51                              
4.3 (2.0) 
 
1                           
10 
 
29                 
3.9 (1.7) 
 
21                   
4.6 (1.9) 
KOOS-P 
     N 
     Mean (SD) 
 
51                              
57.0 (18.9) 
 
1                          
33 
 
29                    
58.7 (17.3) 
 
21                     
55.8 (21.1) 
KOOS-S 
     N 
     Mean (SD) 
 
51                              
56.5 (10.0) 
 
1                           
61 
 
29                   
55.5 (8.1) 
 
21                     
57.5 (12.3) 
KOOS-ADL 
      N 
      Mean (SD) 
 
51                             
60.9 (20.9) 
 
1                           
54 
 
29                     
61.7 (17.3) 
 
21                      
60.2 (25.9) 
KOOS-SP 
     N 
     Mean (SD) 
 
51                            
16.0 (20.3) 
 
1                            
0 
 
29                     
17.9 (18.5) 
 
21                      
14.0 (23.0) 
KOOS-QOL 
     N 
     Mean (SD) 
 
51                              
30.3 (17.7) 
 
1                           
13 
 
29                    
32.2 (17.9) 
 
21                      
28.3 (17.6) 
SF-Mental 
     N 
     Mean (SD) 
 
51                              
49.8 (10.2) 
 
1                          
45.67 
 
29                       
48.9 (10.4) 
 
21                     
51.4 (10.2) 
SF-Physical 
     N 
     Mean (SD) 
 
51                             
36.3 (8.5) 
 
1                           
38.8 
 
29                        
36.9 (8.5) 
 
21                     
35.3 (8.8) 
BB Total Volume 
(cm
3
)
†
 
     N 
     Mean (SD) 
 
 
52                             
12.2 (16.8) 
 
 
1                           
1.7 
 
 
30                             
8.6 (11.1) 
 
 
22                              
18.0 (21.8) 
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Table 4.5 (continued) 
Articular 
Cartilage Damage 
     N 
     Normal 
     Softening 
     Fissuring 
     Fibrillation 
     Defect 
 
 
47                      
33 (70.2)           
8 (17.0)           
5 (10.6)                
0 (0.0)            
 1 (2.1) 
 
 
1                        
1 (100.0)            
0 (0.0)                    
0 (0.0) 
0 (0.0)                
0 (0.0)                 
 
 
28                     
22 (85.2) 
3 (11.1)             
2 (7.4)               
0 (0.0)                
1 (3.7) 
 
 
18                      
10 (55.6)              
5 (27.8)               
3 (16.7)                  
0 (0.0)                   
0 (0.0) 
* sCOMP: serum cartilage oligomeric matrix protein, IKDC: International Knee 
Documentation Committee Subjective Knee Form, IKDC-Pain: International Knee 
Documentation Committee Subjective Knee Form Pain Scale, IKDC-Function: 
International Knee Documentation Committee Subjective Knee Form Function Scale, 
KOOS-P: Knee Injury and Osteoarthritis Outcome Score-Pain, KOOS-S: Knee Injury 
and Osteoarthritis and Outcome Score- Symptoms, KOOS-ADL: Knee Injury and 
Osteoarthritis Outcome Score- Activities of Daily Living, KOOS-SP: Knee Injury and 
Osteoarthritis Outcome Score- Sports and Recreation, KOOS-QOL: Knee Injury and 
Osteoarthritis Outcome Score- Quality of Life, SF-Mental: 12-Item Short Form Health 
Survey Mental Component Score, SF-Physical: Study 12-Item Short Form Health Survey 
Physical Component Score. 
† Total volume is the sum of the volume for each of the lesions present on MRI for the 
patient. 
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Chapter Five: Summary 
Purposes, Aims and Hypotheses 
 The purposes of this dissertation were to determine the inter and intraday 
reliability of serum cartilage oligomeric matrix protein (sCOMP) in a physically active 
cohort; to document the stability of sCOMP in collegiate athletes during athletic 
participation and following acute knee ligament injury (AKLI); to determine if 
differences in sCOMP levels and self-reported pain and function exist for patients 
following AKLI with bone bruise lesions (BBL) and without BBL, and when compared 
according to differing BBL severities. The following specific aims and hypothesis were 
examined throughout the different chapters of this dissertation:  
1. To determine the inter and intraday reliability of sCOMP in a physically active 
cohort. 
 Hypothesis: Serum COMP will have acceptable inter and intraday 
 reliability in a  physically active cohort. 
2. To document the stability of sCOMP over the duration of an athletic season and to 
determine if differences are present following AKLI.  
 Hypothesis1: Serum COMP will remain stable over the duration of an 
 athletic season.   
 Hypothesis2: Serum COMP levels will increase following AKLI. 
3. To determine if differences in sCOMP levels exist between patients with BBL and 
without BBL following AKLI. 
 Hypothesis: Patients with BBL will have higher sCOMP levels compared 
 to patients without BBL. 
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4. To determine if differences in sCOMP levels exist when patients are compared 
according to differing BBL severities (Costa-Paz Classification (CPC)-I, CPC-II, 
CPC-III) following AKLI.  
 Hypothesis: Patients with more severe BBL (CPC-III) will have higher 
 sCOMP levels compared to patients with less severe BBL (CPC-I or 
 CPC-II). 
5. To determine if differences in self-reported pain and function exist between 
patients with BBL and without BBL. 
 Hypothesis: Patients with BBL will have higher levels of self-reported 
 pain and more functional limitations compared to patients without BBL. 
6. To determine if differences in self-reported pain and function exist when patients 
are compared according to differing BBL severities (CPC-I, CPC-II, CPC-III) 
following ALKI. 
 Hypothesis: Patients with more severe BBL (CPC-III) will report higher 
 levels of self-reported pain and functional limitations compared to patients 
 with less severe BBL (CPC-I or CPC-II). 
Summary of Findings 
 The following are summaries of the findings for each of the specific aims: 
1. To determine the inter and intraday reliability of sCOMP in a non-elite, physically 
active cohort. 
 Finding: The hypothesis was confirmed, the results of this study 
 demonstrated  strong inter and intraday reliability for sCOMP values in a 
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 healthy, physically active cohort with no history of lower extremity 
 surgery.  
2. To document the stability of sCOMP over the duration of an athletic season and to 
determine if differences are present following AKLI.  
 Finding1: The hypothesis was rejected; the results demonstrated sCOMP 
 levels do not remain stable in healthy collegiate level soccer players over 
 the duration of a soccer season. However, the difference between each of 
 the time points was less than the calculated intersession MDC value (464.6 
 ng/mL), indicating these elevations were not clinically meaningful.  
 Finding2: The second hypothesis was confirmed as the results 
 demonstrated significant elevations in sCOMP immediately following 
 AKLI. However, these results must be interpreted with caution as only one 
 subject sustained an ACL injury. Interestingly the results demonstrated a 
 significant elevation in sCOMP levels prior to AKLI. 
3. To determine if differences in sCOMP levels exist between patients with BBL and 
without BBL following AKLI. 
 Finding: The hypothesis was rejected; there were no differences in 
 sCOMP levels between patients with and without BBL. 
4. To determine if differences in sCOMP levels exist when patients are compared 
according to differing BBL severities (CPC-I, CPC-II, CPC-III) following AKLI.  
 Finding: The hypothesis was rejected; there were no differences in 
 sCOMP levels when patients were compared according to differing 
 BBL severities. 
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5. To determine if differences in self-reported pain and function exist between 
patients with BBL and without BBL. 
 Finding: The hypothesis was confirmed for the KOOS-ADL, as patients 
 with BBL reported more functional limitations related to knee 
 symptoms when performing ADLs when compared to patients 
 without BBL. For all other variables of function (KOOS-SP, IKDC-
 Function, SF-Physical), the hypothesis was rejected. Additionally, for 
 the variables that were used to measure pain (KOOS-P and  IKDC- Pain), 
 the hypothesis was rejected. 
6. To determine if differences in self-reported pain and function exist when patients 
are compared according to differing BBL severities (BBL absent, CPC-I, CPC-II, 
CPC-III) following ALKI. 
 Finding: The hypothesis was confirmed for the KOOS-SP, as patients 
 with BBL reported more functional limitations when performing sports 
 related activities when compared to patients without BBL. For all other 
 variables of function (KOOS-ADL, IKDC-Function, SF-Physical),  the 
 hypothesis was rejected. Additionally, for the variables that were used 
 to measure pain (KOOS-P and IKDC-Pain),  the hypothesis was rejected.  
Synthesis of Results and Future Research Implications  
  From these studies several conclusions and suggestions for future research were 
able to be made.  
1. Serum COMP is a reliable marker in subjects who participate in physical 
activity. Therefore, increases in sCOMP levels are likely due to articular 
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cartilage damage or increased turnover and are not due to day to day 
fluctuations.36 In addition, these results supported previous recommendations 
that sCOMP levels can be collected at different time points throughout the day 
for clinical research studies.1 In addition, our results support the collection of 
non-fasting samples for future research studies as consuming meals 
throughout the day was not controlled in our sample. The ability to collect 
samples during the waking hours and regardless of whether or not patients 
have consumed food is important for the utility of this marker in clinical 
populations and the clinical setting.   
2. Serum COMP levels do not remain stable over the duration of an athletic 
season. While these elevations were not considered clinically meaningful 
when employing the calculated MDC value, knowledge of this phenomenon is 
important for future research studies. While the amount of participation the 
athletes were engaged in was not quantified, understanding that biomarkers 
are increased at different points in the season may be important in 
understanding the results of future clinical research studies investigating 
changes in biomarkers following AKLI. Additionally, future research studies 
should aim to determine whether or not  fluctuations in sCOMP levels are due 
to increase in turnover or irreversible joint damage as this would shed light on 
the findings of this study. 
3. Our results confirm previous results that documented increases in sCOMP 
levels following AKLI.47 While there was only one subject included in this 
analysis, the results indicate that there are measurable differences in sCOMP 
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following AKLI compared to a cohort who, a) had no history of lower 
extremity surgery and b) participated in the same levels of athletic activity. 
However, we must point out that the injured serum was collected roughly one 
hour following her injury and there was a decrease in her sCOMP levels at her 
time of surgery. These results further demonstrate sCOMP levels are most 
elevated immediately after injury and decrease as time elapses from the 
injury.13, 58 These results, in combination with previous research studies, 
support the use of sCOMP as a biomarker for understanding the degree of 
acute articular damage following AKLI.24 Furthermore, these results indicated 
that sCOMP levels are elevated immediately prior to AKLI. Again, while this 
phenomenon was observed in only one subject, future research studies 
investigating the utility of this marker or other markers as predictors of AKLI 
may be necessary. 
4. There were no measurable differences in sCOMP levels between patients with 
and without BBL or between differing BBL severities (CPC-II and CPC-III) 
following AKLI. Differences may have been elusive because sCOMP was not 
specific enough to detect such small changes or too much time elapsed from 
time of injury to serum collection. Should this be true; one must question the 
use of this marker for future clinical research studies as the need to collect 
these samples relatively acutely may not be feasible for some researchers or 
clinicians.  
5. There were differences in the KOOS-ADL for patients with BBL when 
compared to patients without BBL. However, we detected no differences in 
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pain between the two groups. Additionally, differences in KOOS-SP were 
detected for patients with more severe BBL when compared to patients 
without BBL. Furthermore, we detected no differences in pain between the 
two severity groups. Keeping in mind that our BBL absent group was 
relatively small (n=7) and we had only one patient in the CPC-I group, these 
findings should be reviewed with caution. However, based on these results, 
integrating a BBL severity classification into future research studies may be 
able to better explain clinical phenomena, such as differences in self-reported 
pain and function. 
Conclusions 
 This dissertation investigated the use of sCOMP as a biomarker for acute articular 
cartilage damage. Serum COMP is a biomarker that has been studied extensively in the 
osteoarthritis literature,15, 43 a chronic articular cartilage disease. Recent literature has 
suggested that people who participate in intense exercise12, 48 or for those who succumb 
to AKLI, regardless of whether they have ligament reconstruction or not,54, 57, 91  may 
develop degenerative articular cartilage disease. We hypothesized sCOMP would be a 
viable marker to better understand acute articular cartilage damage associated with 
exercise and ALKI.  
 Serum COMP levels demonstrate strong inter and intraday reliability in subjects 
who engage in physical activity. We noted that sCOMP levels did not remain stable over 
the duration of an athletic season. While these changes did not exceed the calculated 
MDC value, sCOMP may useful to document the long term effects of exercise on 
articular cartilage. Additionally, differences were noted following AKLI in one subject 
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when compared to an uninjured cohort. However, we did not detect differences in 
sCOMP levels between patients with and without BBL, or differing BBL severities. 
While these results were insignificant, there may exist additional biomarkers that may be 
appropriate such as synovial fluid COMP.  Synovial fluid COMP may be a more specific 
marker of acute cartilage damage that requires further analysis. Additionally, while a 
majority of these patients did not have visible articular cartilage damage when viewed 
during arthroscopy, a more specific documentation of articular cartilage injury overlying 
these lesions, such as biopsies, may be necessary to further understand the damage that is 
sustained to the overlying articular cartilage. In summary, while it appears sCOMP 
maybe not be a viable marker for understanding the acute articular cartilage damage 
associated with AKLI, it does appear to be useful for studies investigating the effects of 
intense exercise on articular cartilage.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Copyright © Johanna M. Hoch 2012
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Appendix A: International Knee Documentation Committee (IKDC) 
Patient Name________________________ ID _____________________   Side  Right  Left  
Date of review:  __/__/__ OR Follow up period:  PreOp  OR__weeks/months/years (circle one) 
SYMPTOMS*: 
*Grade symptoms at the highest activity level at which you think you could function without significant 
symptoms, even if you are not actually performing activities at this level. 
 
1. What is the highest level of activity that you can perform without significant knee pain? 
Very strenuous activities like jumping or pivoting as in basketball or soccer 
Strenuous activities like heavy physical work, skiing or tennis 
Moderate activities like moderate physical work, running or jogging 
Light activities like walking, housework or yard work 
Unable to perform any of the above activities due to knee pain 
 
2. During the past 4 weeks, or since your injury, how often have you had pain? 
Never 0 1 2 3 4 5 6 7 8 9 10 Constant 
 
           
 
 
3. If you have pain, how severe is it? 
No pain 0 1 2 3 4 5 6 7 8 9 10 Worst Pain Imaginable 
 
           
 
 
4. During the past 4 weeks, or since your injury, how stiff or swollen was your knee? 
Not at all Mildly Moderately Very Extremely 
 
5. What is the highest level of activity you can perform without significant swelling in your knee? 
Very strenuous activities like jumping or pivoting as in basketball or soccer 
Strenuous activities like heavy physical work, skiing or tennis 
Moderate activities like moderate physical work, running or jogging 
Light activities like walking, housework, or yard work 
Unable to perform any of the above activities due to knee swelling 
 
6. During the past 4 weeks, or since your injury, did your knee lock or catch? 
Yes   No 
 
7. What is the highest level of activity you can perform without significant giving way in your knee? 
Very strenuous activities like jumping or pivoting as in basketball or soccer 
Strenuous activities like heavy physical work, skiing or tennis 
Moderate activities like moderate physical work, running or jogging 
Light activities like walking, housework or yard work 
Unable to perform any of the above activities due to giving way of the knee 
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SPORTS ACTIVITIES: 
 
8. What is the highest level of activity you can participate in on a regular basis? 
Very strenuous activities like jumping or pivoting as in basketball or soccer 
Strenuous activities like heavy physical work, skiing or tennis 
Moderate activities like moderate physical work, running or jogging 
Light activities like walking, housework or yard work 
Unable to perform any of the above activities due to knee 
 
9. How does your knee affect your ability to: 
  
Not 
difficult 
at all 
Minimally 
difficult 
Moderately 
Difficult 
Extremely 
difficult 
Unable 
to do 
a. Go up stairs      
b. Go down stairs      
c. Kneel on the front of your knee      
d. Squat      
e. Sit with your knee bent      
f. Rise from a chair      
g. Run straight ahead      
h. Jump and land on your involved leg      
i. Stop and start quickly      
 
FUNCTION: 
10. How would you rate the function of your knee on a scale of 0 to 10 with 10 being normal, excellent 
function and 0 being the inability to perform any of your usual daily activities which may include 
sports? 
 
FUNCTION PRIOR TO YOUR KNEE INJURY: 
Cannot perform 
daily activities  
 
0 1 2 3 4 5 6 7 8 9 10 No limitation 
           
 
 
CURRENT FUNCTION OF YOUR KNEE: 
Cannot perform 
daily activities 
 
0 1 2 3 4 5 6 7 8 9 10 No limitation 
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Appendix B: Knee Injury and Osteoarthritis Outcome Survey 
Patient Name________________________________________________ Patient ID ____________________  
Side  Right  Left     Study Name ___________Study Number________________ 
Date_____/______/______ or PreOp  weeks/months/years (circle one) 
Filled in by: Operating Dr. Other MD Research Assistant Questionnaire Other 
Reviewer Name: _____________________________Next Visit Due _____/______/______ 
INSTRUCTIONS: This survey asks for your view about your knee. This information will help us keep track of 
how you feel about your knee and how well you are able to do your usual activities. Answer every question 
by ticking the appropriate box, only one box for each question. If you are unsure about how to answer a 
question, please give the best answer you can. 
 
Symptoms 
These questions should be answered thinking of your knee symptoms during the last week. 
S1. Do you have swelling in your knee? 
 Never Rarely Sometimes Often Always 
S2. Do you feel grinding, hear clicking or any other type of noise when your knee moves? 
 Never Rarely Sometimes Often Always 
S3. Does your knee catch or hang up when moving? 
 Never Rarely Sometimes Often Always 
S4. Can you straighten your knee fully? 
  Always  Often Sometimes  Rarely  Never 
S5. Can you bend your knee fully? 
  Always  Often Sometimes  Rarely  Never 
 
Stiffness 
The following questions concern the amount of joint stiffness you have experienced during the last week in 
your knee. Stiffness is a sensation of restriction or slowness in the ease with which you move your knee joint. 
S6. How severe is your knee joint stiffness after first wakening in the morning? 
 None Mild Moderate Severe Extreme 
S7. How severe is your knee stiffness after sitting, lying or resting later in the day? 
 None Mild Moderate Severe Extreme 
 
Pain 
P1. How often do you experience knee pain? 
 Never Monthly Weekly Daily Always 
 
What amount of knee pain have you experienced the last week during the following activities? 
P2. Twisting/pivoting on your knee 
 None Mild Moderate Severe Extreme 
P3. Straightening knee fully 
 None Mild Moderate Severe Extreme 
P4. Bending knee fully 
 None Mild Moderate Severe Extreme 
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Pain, continued 
P5. Walking on flat surface 
 None Mild Moderate Severe Extreme 
P6. Going up or down stairs 
 None Mild Moderate Severe Extreme 
P7. At night while in bed 
 None Mild Moderate Severe Extreme 
P8. Sitting or lying 
 None Mild Moderate Severe Extreme 
P9. Standing upright 
 None Mild Moderate Severe Extreme 
 
Function, daily living 
The following questions concern your physical function. By this we mean your ability to move around and 
to look after yourself. For each of the following activities please indicate the degree of difficulty you have 
experienced in the last week due to your knee. 
A1. Descending stairs 
 None Mild Moderate Severe Extreme 
A2. Ascending stairs 
 None Mild Moderate Severe Extreme 
A3. Rising from sitting 
 None Mild Moderate Severe Extreme 
A4. Standing 
 None Mild Moderate Severe Extreme 
A5. Bending to floor/pick up an object 
 None Mild Moderate Severe Extreme 
A6. Walking on flat surface 
 None Mild Moderate Severe Extreme 
A7. Getting in/out of car 
 None Mild Moderate Severe Extreme 
A8. Going shopping 
 None Mild Moderate Severe Extreme 
A9. Putting on socks/stockings 
 None Mild Moderate Severe Extreme 
A10. Rising from bed 
 None Mild Moderate Severe Extreme 
A11. Taking off socks/stockings 
 None Mild Moderate Severe Extreme 
A12. Lying in bed (turning over, maintaining knee position) 
 None Mild Moderate Severe Extreme 
A13. Getting in/out of bath 
 None Mild Moderate Severe Extreme 
 
103 
 
 
For each of the following activities please indicate the degree of difficulty you have experienced in the last 
week due to your knee. 
A14. Sitting 
 None Mild Moderate Severe Extreme 
A15. Getting on/off toilet 
 None Mild Moderate Severe Extreme 
A16. Heavy domestic duties (moving heavy boxes, scrubbing floors, etc) 
 None Mild Moderate Severe Extreme 
A17. Light domestic duties (cooking, dusting, etc) 
 None Mild Moderate Severe Extreme 
 
Function, sports and recreational activities 
The following questions concern your physical function when being active on a higher level. The questions 
should be answered thinking of what degree of difficulty you have experienced during the last week due 
to your knee.  
SP1. Squatting 
 None Mild Moderate Severe Extreme 
SP2. Running 
 None Mild Moderate Severe Extreme 
SP3. Jumping 
 None Mild Moderate Severe Extreme 
SP4. Twisting/pivoting on your injured knee 
 None Mild Moderate Severe Extreme 
SP5. Kneeling 
 None Mild Moderate Severe Extreme 
 
Quality of Life 
Q1. How often are you aware of your knee problem? 
 Never Monthly Weekly Daily Constantly 
Q2. Have you modified your life style to avoid potentially damaging activities to your knee? 
 Not at all Mildly Moderately Severely Totally 
Q3. How much are you troubled with lack of confidence in your knee? 
 Not at all Mildly Moderately Severely Extremely 
Q4. In general, how much difficulty do you have with your knee? 
 None Mild Moderate Severe Extreme 
 
 
 
Thank you very much for completing all the questions in this questionnaire. 
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Appendix C: 12 Item Short Form Health Survey 
Patient Name________________________________________________Patient ID _____________________  
Side  Right  Left  Study Name _____Study Number_______Date___/____/____ or PreOp  
weeks/months/years (circle one) 
Filled in by: Operating Dr. Other MD Research Assistant Questionnaire  Other 
Reviewer Name: _____________________________Next Visit Due _____/______/______ 
  1)  In general, would you say your health is: 
Excellent 
Very Good 
Good  
Fair 
Poor 
 2) The following questions are about activities you might do during a typical day.  
 Does your health now limit you in these activities? 
If so, how much? 
  Yes, limited 
a lot 
Yes, limited 
a little 
No, not 
limited at all 
 Moderate activities, such as moving a table,  
pushing a vacuum cleaner, bowling, or playing golf  
   
 Climbing several flights of stairs     
 
 3) During the past 4 weeks, how much of the time have you had any of the following problems 
with  your work or other regular daily activities as a result of your physical health? 
 
 
 All of the 
time 
Most of  
the time 
Some of  
the time 
A little  
of the time 
None of  
the time 
Accomplished less than you would like      
Were limited in the kind of work or other 
activities 
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4) During the past 4 weeks, how much of the time have you had any of the following problems 
with your work or other regular daily activities as a result of any emotional problems (such as 
feeling depressed or anxious) 
 All of  
the time 
Most of the  
time 
Some of  
the time 
A little of  
the time 
None  
of the 
time 
Accomplished less than you would like      
Did work or other activities less carefully than 
usual  
     
  
5) During the past 4 weeks, how much did pain interfere with your normal work (including both 
work outside the home and housework)? 
Not at All 
A Little Bit 
Moderately 
Quite a Bit 
Extremely 
   These questions are about how you feel and how things have been with you during the past 4 
weeks. For each question, please give the one answer that comes closest to the way you have 
been feeling.  
   How much of the time during the past 4 weeks… 
 All of the 
 time 
Most of  
the time 
Some of  
the time 
A little of 
 the time 
None of  
the time 
Have you felt calm and peaceful?       
Did you have a lot of energy?       
Have you felt downhearted and depressed?       
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During the past 4 weeks, how much of the time has your physical health or emotional problems 
interfered with your social activities (like visiting with friends, relatives, etc.)? 
All of the time 
Most of the time 
Some of the time 
A little of the time 
None of the time 
This form includes questions from the SF-36TM Health Survey. Reproduced with the permission of the Medical Outcomes Trust, 
Copyright © 1992. 
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